https://crcwarriors.org/ 2026-06-02 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-06-02 daily 0.9 https://crcwarriors.org/medicamentos 2026-06-02 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-06-02 daily 0.8 https://crcwarriors.org/noticias 2026-06-02 daily 0.8 https://crcwarriors.org/combinaciones 2026-06-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-06-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-06-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-06-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-06-01 monthly 0.7 https://crcwarriors.org/contacto 2026-06-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-06-01 monthly 0.6 https://crcwarriors.org/colabora 2026-06-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07617610/resistencia-primaria-y-adquirida-al-tratamiento-dirigido-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/primary-and-acquired-resistance-to-targeted-treatment-in-braf-v600e-mutated-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07616297/una-dosis-de-radiacion-mas-alta-dirigida-al-tumor-podria-ayudar-a-evitar-la-cirugia-en-pacientes-con-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07616297/higher-radiation-dose-to-the-tumor-may-help-avoid-surgery-in-rectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678648/un-ensayo-clinico-de-rsc-1255-para-el-tratamiento-de-pacientes-con-tumores-malignos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678648/a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014372/envafolimab-como-monoterapia-o-envafolimab-capeox-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014372/envafolimab-monotherapy-or-envafolimab-capeox-as-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/un-estudio-de-fase-ii-realizado-en-un-unico-centro-sobre-la-eficacia-y-la-seguridad-de-la-combinacion-de-radioterapia-estereotactica-scrt-con-quimioterapia-capox-serplulimab-y-bevacizumab-en 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07347951/a-single-center-phase-ii-study-on-efficacy-safety-of-scrt-capox-serplulimab-bevacizumab-for-mss-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05585814/capeox-en-combinacion-con-bevacizumab-mas-un-anticuerpo-anti-pd1-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-microsatelital 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05585814/capeox-combined-with-bevacizumab-plus-anti-pd1-antibody-as-neoadjuvant-therapy-for-microsatellite-stable-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02572141/quimioterapia-perioperatoria-con-folfox-o-capox-frente-a-quimioterapia-postoperatoria-para-el-cancer-colorrectal-localmente-avanzado-optical 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/folfox-or-capox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-colon-cancer-optical 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-en-combinacion-con-quimiorradioterapia-neoadyuvante-como-tratamiento-de-primera-linea-para-el-cancer-de-recto-localmente-avanzado-de-alto-riesgo-y-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05877573/toripalimab-combined-with-neoadjuvant-chemoradiotherapy-as-first-line-treatment-for-locally-advanced-high-risk-mss-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244537/estudio-sobre-la-seguridad-y-la-eficacia-de-la-tecnica-mr-linac-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244537/study-on-the-safety-and-efficacy-of-mr-linac-technique-in-patients-with-unresectable-locally-advanced-colon-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645301/bgt007-tratamiento-para-tumores-gastrointestinales-recurrentes-o-refractarios 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06645301/bgt007-treatment-for-recurrent-refractory-gastrointestinal-malignancies 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06884670/evaluacion-de-la-eficacia-y-la-seguridad-del-anticuerpo-monoclonal-anti-pd-1-en-combinacion-con-il-2-y-capeox-en-la-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-previo-a-la 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06884670/assessment-of-efficacy-and-safety-of-pd-1-monoclonal-antibody-combined-with-il-2-and-capeox-in-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-prior-to-surgery-a-prospective-multi-center 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05212012/d-l-metadona-y-mfolfox6-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-methadone-and-mfolfox6-in-treatment-of-advanced-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/estudio-multidimensional-disenado-para-desarrollar-un-marco-metodologico-basado-en-datos-de-resonancia-magnetica-rm-con-el-fin-de-predecir-la-respuesta-patologica-completa-pcr-en-pacientes-con-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07404228/multidimensional-study-designed-to-develop-a-methodological-framework-based-on-mri-data-to-predict-pathological-complete-response-pcr-in-patients-with-locally-advanced-rectal-cancer-after-neoadjuvant 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06229340/leflunomida-o-combinacion-de-un-inhibidor-de-mek-e-hidroxicloroquina-para-pacientes-con-mutaciones-en-ras-que-no-responden-al-tratamiento 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomide-or-combination-of-mek-inhibitor-and-hydroxychloroquine-for-refractory-patients-with-ras-mutations 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596343/evaluacion-de-los-beneficios-de-la-medicina-tradicional-china-personalizada-en-el-tratamiento-postoperatorio-del-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06596343/evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06516445/radioterapia-de-corta-duracion-seguida-de-camrelizumab-en-combinacion-con-fluzoparib-y-quimioterapia-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06516445/scrt-followed-by-camrelizumab-combined-with-fluzoparib-and-chemotherapy-as-neoadjuvant-therapy-for-larc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07176182/ensayo-clinico-de-mfolfox-neoadyuvante-mas-alvenor-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-con-alta-expresion-de-ywhab 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/clinical-trial-of-neoadjuvant-mfolfox-plus-alvenor-for-larc-patients-with-high-ywhab-expression 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281157/irinotecano-liposomal-mas-capecitabina-y-enronsubemab-en-combinacion-con-radioterapia-de-corta-duracion-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281157/irinotecan-liposome-plus-capecitabine-and-enronsubemab-combined-with-short-course-radiotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07467590/combinacion-de-radioterapia-en-dosis-altas-y-bajas-con-inmunoterapia-y-tki-en-cancer-colorrectal-avanzado-un-estudio-de-fase-ii 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07467590/combination-of-high-and-low-dose-radiotherapy-with-immune-therapy-and-tki-in-advanced-colorectal-cancer-a-phase-ii-study 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05576896/hidroxicloroquina-en-combinacion-con-encorafenib-y-cetuximab-o-panitumumab-en-el-tratamiento-del-cancer-colorrectal-metastasico-con-mutacion-braf-refractario 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576896/hydroxychloroquine-in-combination-with-encorafenib-and-cetuximab-or-panitumumab-in-the-treatment-of-metastatic-braf-mutated-colorectal-cancer-refractory 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05945901/un-estudio-de-fase-ii-iii-de-hr070803-en-combinacion-con-oxaliplatino-5-fluorouracilo-folinato-de-calcio-y-bevacizumab-frente-a-folfox-en-combinacion-con-bevacizumab-para-el-tratamiento-de-primera 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05945901/a-phase-ii-iii-study-of-hr070803-in-combination-with-oxaliplatin-5-fluorouracil-calcium-folinate-and-bevacizumab-versus-folfox-in-combination-with-bevacizumab-for-first-line-treatment-of-advanced 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201259/analisis-de-las-diferencias-en-el-microbioma-intestinal-de-pacientes-con-cancer-y-diferentes-niveles-de-funcion-ovarica-y-resultados-de-fertilidad-tras-la-terapia-con-inhibidores-de-puntos-de-control 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201259/exploring-gut-microbiome-differences-in-female-cancer-patients-with-varied-ovarian-function-and-fertility-outcomes-following-immune-checkpoint-inhibitor-therapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965335/cancer-colorrectal-de-inicio-temprano-un-estudio-observacional-retrospectivo-y-prospectivo-multicentrico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965335/early-onset-colorectal-cancer-an-observational-retrospective-and-prospective-multicenter-study 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05457244/seguridad-y-rendimiento-del-sistema-quirurgico-da-vinci-sp-r-en-procedimientos-de-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05457244/safety-and-performance-of-the-da-vinci-sp-r-surgical-system-in-colorectal-procedures 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/tislelizumab-neoadyuvante-en-combinacion-con-quimioterapia-para-el-tratamiento-del-cancer-colorrectal-mss 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/neoadjuvant-tislelizumab-with-chemotherapy-for-the-treatment-of-mss-colon-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-un-farmaco-inhibidor-de-mkk4-de-primera-generacion-para-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-someterse-a-una-embolizacion-de-la-vena-porta 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-a-first-generation-mkk4-inhibitor-drug-for-the-treatment-of-patients-with-colorectal-liver-metastasis-after-undergoing-a-portal-vein-embolization 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614699/efecto-predictivo-de-la-grasa-abdominal-y-el-area-muscular-calculados-a-partir-de-una-tomografia-computarizada-tc-abdominal-en-pacientes-con-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614699/predictive-effect-of-abdominal-fat-and-muscle-area-calculated-based-on-abdominal-ct-on-colorectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06293625/personalizacion-y-optimizacion-de-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-pero-resecable-en-pacientes-de-edad-avanzada-de-70-anos-o-mas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalising-and-refining-neo-adjuvant-chemotherapy-in-locally-advanced-but-resecable-colon-cancer-in-the-elderly-of-70-years-old-or-more 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combinado-con-capox-y-un-inhibidor-de-pd-1-para-el-cancer-colorrectal-de-alto-riesgo 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combined-with-capox-and-pd-1-for-high-risk-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612436/ainc-intervencion-basada-en-inteligencia-artificial-para-mejorar-la-realizacion-de-colonoscopias 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612436/ai-empowered-nudge-to-improve-colonoscopy-uptake-ainc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/estudio-de-fase-ii-de-encorafenib-mas-cetuximab-con-retratamiento-guiado-por-ctdna-en-pacientes-con-mcrc-con-mutacion-braf-v600e 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/phase-ii-study-of-ctdna-guided-encorafenib-plus-cetuximab-retreatment-in-patients-braf-v600e-mutated-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07158164/farmacogenomica-de-dpyd-y-ajuste-de-la-dosis-de-fluoropirimidinas-fp 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07158164/dpyd-pharmacogenomics-and-fluoropyrimidine-fp-dose-adjustment 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07108127/eficacia-y-seguridad-de-los-biosimilares-de-trastuzumab-y-los-biosimilares-de-pertuzumab-en-combinacion-con-quimioterapia-para-el-tratamiento-neoadyuvante-de-pacientes-con-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07108127/efficacy-and-safety-of-trastuzumab-biosimilars-and-pertuzumab-biosimilars-combined-with-chemotherapy-for-neoadjuvant-treatment-of-patients-with-locally-advanced-her2-positive-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06301386/everolimus-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-combined-with-pd-1-in-advanced-colorectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07505472/comparacion-de-la-eficacia-y-la-seguridad-de-un-ciclo-corto-de-radioterapia-seguido-de-quimioterapia-con-capeox-mas-toripalimab-con-o-sin-surufatinib-concomitante-en-la-terapia-neoadyuvante-para-el 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04556253/ak104-en-el-carcinoma-gastrico-y-el-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-in-locally-advanced-msi-h-dmmr-gastric-carcinoma-and-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05990543/combinacion-de-nelmastobart-y-capecitabina-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05990543/combination-of-nelmastobart-and-capecitabine-therapy-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-perfilado-y-abordaje-de-la-resistencia-tumoral-dinamica-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-profiling-and-targeting-dynamic-tumor-resistance-in-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04034173/tratamiento-optimo-con-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-ras-de-baja-frecuencia 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04034173/optimal-anti-egfr-treatment-of-mcrc-patients-with-low-frequency-ras-mutation 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06282445/eficacia-y-seguridad-de-la-quimioterapia-con-xelox-oxaliplatino-capecitabina-y-bevacizumab-en-combinacion-con-adebrelimab-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06282445/efficacy-and-safety-of-chemotherapy-with-xelox-oxaliplatin-capecitabine-and-bevacizumab-in-combination-with-adebrelimab-in-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-putalimab-in-the-treatment-of-patients-with-mcrc-after-cytoreductive-surgery-a-single-arm-single-center-clinical 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/un-estudio-de-amivantamab-y-mfolfox6-o-folfiri-frente-a-cetuximab-y-mfolfox6-o-folfiri-como-tratamiento-de-primera-linea-en-participantes-con-cancer-colorrectal-irresecable-o-metastasico-del-lado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662786/a-study-of-amivantamab-and-mfolfox6-or-folfiri-versus-cetuximab-and-mfolfox6-or-folfiri-as-first-line-treatment-in-participants-with-kras-nras-and-braf-wild-type-unresectable-or-metastatic-left-sided 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05856305/terapia-de-radiacion-estereotactica-en-tumores-del-tracto-nervioso-con-o-sin-clorofilina 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/scrt-in-tnt-with-or-without-chlorophyllin 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05704985/evaluacion-de-la-seguridad-y-los-biomarcadores-mediante-el-uso-de-dk210-egfr-en-tumores-localmente-avanzados-o-metastasicos-egfr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05704985/evaluating-safety-and-biomarkers-using-dk210-egfr-for-locally-advanced-or-metastatic-egfr-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/tratamiento-neoadyuvante-con-mfolfoxiri-mas-cadonilimab-ak104-frente-a-mfolfox6-en-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05571644/neoadjuvant-treatment-with-mfolfoxiri-plus-cadonilimab-ak104-versus-mfolfox6-in-locally-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/inhibidor-de-mnk-aum001-en-combinacion-con-pembrolizumab-o-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462236/mnk-inhibitor-aum001-in-combination-with-either-pembrolizumab-or-irinotecan-to-treat-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05973487/un-estudio-basket-de-terapias-celulares-autologas-de-tcr-t-personalizadas-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/a-basket-study-of-customized-autologous-tcr-t-cell-therapies-in-patients-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05645094/envafolimab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-y-resecable-con-msi-h-dmmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05645094/neoadjuvant-envafolimab-in-resectable-and-locally-advanced-msi-h-dmmr-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06794931/estudio-sobre-el-impacto-de-una-dieta-mediterranea-modificada-en-pacientes-con-cancer-colorrectal-que-reciben-tratamiento-oncologico-activo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06794931/study-on-the-impact-of-a-modified-mediterranean-diet-in-patients-with-colorectal-cancer-undergoing-active-medical-oncology-treatment 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluacion-de-la-enfermedad-metastasica-y-del-tratamiento-oncologico-en-pacientes-con-cancer-de-colon-mediante-el-uso-de-avatares-de-pez-cebra 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluation-of-metastatic-disease-and-oncological-treatment-in-patients-with-colon-cancer-using-zebra-fish-avatars 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06133439/deteccion-del-cancer-colorrectal-en-zonas-rurales-de-indiana 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06133439/rural-indiana-screening-for-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337590/seguridad-y-vigilancia-de-la-anastomosis-mediante-el-uso-de-sensores-mejorados-en-tiempo-real-con-xbar 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337590/anastomotic-safety-and-surveillance-using-real-time-enhanced-sensing-using-xbar 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07038122/reduccion-del-margen-de-reseccion-tras-la-terapia-neoadyuvante-en-canceres-localmente-avanzados-de-la-union-rectosigmoidea-y-del-recto-superior 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07038122/reducing-the-resection-range-after-neoadjuvant-therapy-for-locally-advanced-upper-rectal-and-rectosigmoid-junction-cancers 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-y-pembrolizumab-en-el-tratamiento-de-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-and-pembrolizumab-in-treating-participants-with-advanced-or-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07540572/un-estudio-para-investigar-la-seguridad-la-farmacocinetica-y-la-eficacia-preliminar-de-la-terapia-con-ide574-en-participantes-adultos-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07540572/a-study-to-investigate-the-safety-pharmacokinetics-and-preliminary-efficacy-of-ide574-therapy-in-adult-participants-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020468/terapia-neoadyuvante-nalirifox-para-el-cancer-colorrectal-localmente-avanzado-y-el-cancer-del-recto-superior 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07020468/neoadjuvant-therapy-nalirifox-for-locally-advanced-colon-and-upper-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04894370/combinacion-de-spartalizumab-mdcf-y-radioterapia-en-pacientes-con-carcinoma-anal-de-celulas-escamosas-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04894370/combination-of-spartalizumab-mdcf-and-radiotherapy-in-patients-with-metastatic-squamous-cell-anal-carcinoma 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06763432/resultados-positivos-en-la-prueba-de-deteccion-fecal-superando-las-limitaciones 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06763432/positive-fit-to-colonoscopy-closing-the-gap 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/un-estudio-sobre-la-eficacia-y-la-seguridad-de-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-el-tratamiento-de-la-crclm 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/cohorte-nacional-prospectiva-para-evaluar-biomarcadores-predictivos-de-resistencia-a-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-dmmr-coresim 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06353854/prospective-national-cohort-evaluating-predictive-biomarkers-of-resistance-to-immunotherapy-in-patients-with-msi-dmmr-metastatic-colorectal-cancer-coresim 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/imagen-pet-de-dos-vartumabs-en-pacientes-con-tumores-solidos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645808/pet-imaging-of-two-vartumabs-in-patients-with-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787587/un-estudio-del-inhibidor-de-parg-ide161-en-participantes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787587/a-study-of-parg-inhibitor-ide161-in-participants-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07153016/asesoramiento-juridico-y-defensa-de-los-derechos-de-los-cuidadores-legacy-care-un-ensayo-clinico-piloto-para-los-cuidadores-de-personas-con-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07153016/legal-guidance-and-advocacy-for-caregivers-legacy-care-a-pilot-clinical-trial-for-caregivers-of-persons-with-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/mesalazina-como-tratamiento-profilactico-para-prevenir-la-colitis-tras-el-tratamiento-con-ipilimumab-nivolumab-ipi-nivo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663775/prophylactic-mesalamine-to-prevent-colitis-following-treatment-with-ipilimumab-nivolumab-ipi-nivo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998745/el-impacto-del-modelo-mtm-en-la-eficacia-y-la-seguridad-de-la-terapia-anticoagulante-en-pacientes-con-cancer-colorrectal-en-el-periodo-postoperatorio 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998745/the-impact-of-mtm-model-on-the-efficacy-and-safety-of-anticoagulant-therapy-in-postoperative-colorectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359989/leucina-mas-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucine-plus-radiochemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/preservacion-de-organos-en-el-cancer-de-recto-braquiterapia-de-contacto-con-rayos-x-frente-a-la-prolongacion-del-intervalo-de-espera-y-la-escision-local 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05501353/exploracion-de-biomarcadores-asociados-con-el-pronostico-del-cancer-colorrectal-recurrente-y-metastasico-tras-la-cirugia-mediante-metodos-multiomicos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/explore-biomarkers-associated-with-prognosis-of-recurrent-and-metastatic-crc-after-surgery-by-multi-omics-methods 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/estudio-de-inmunoterapia-con-timalfasina-y-regimen-triple-en-cancer-colorrectal-avanzado-mss-pmmr 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/thymalfasin-immunotherapy-study-with-triple-regimen-in-advanced-mss-pmmr-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/eficacia-y-seguridad-de-la-terapia-neoadyuvante-convencional-frente-a-la-terapia-neoadyuvante-total-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07365527/sonoporacion-y-respuesta-del-microambiente-tumoral-en-metastasis-hepaticas-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05487248/un-estudio-de-los-cambios-en-el-ctdna-durante-el-tratamiento-en-pacientes-con-cancer-colorrectal-resistente-a-la-quimioterapia 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05487248/a-study-of-on-treatment-ctdna-changes-in-chemo-refractory-colorectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07044362/histotripsia-mas-quimioterapia-frente-a-quimioterapia-sola-en-metastasis-hepaticas-avanzadas-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsy-plus-chemotherapy-vs-chemotherapy-alone-for-advanced-colorectal-liver-metastasis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/estudio-prospectivo-multicentrico-a-nivel-nacional-para-evaluar-los-factores-pronosticos-relacionados-con-la-eficacia-del-tratamiento-con-fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07124858/prospective-national-cohort-evaluating-prognostic-factors-for-efficacy-of-fruquintinib-treatment-in-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07183124/modelado-tridimensional-para-la-deteccion-del-cancer-colorrectal-localmente-avanzado-con-margenes-de-reseccion-circunferencial-positivos 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/3d-modeling-for-detecting-locally-advanced-rectal-cancer-with-positive-circumferential-resection-margin 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05571839/un-estudio-de-pf-08046049-sgn-bb228-en-melanoma-avanzado-y-otros-tumores-solidos 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05571839/a-study-of-pf-08046049-sgn-bb228-in-advanced-melanoma-and-other-solid-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05275374/xp-102-y-xp-102-en-combinacion-con-trametinib-en-pacientes-con-tumores-solidos-avanzados-y-una-mutacion-braf-v600 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05275374/xp-102-and-xp-102-in-combination-with-trametinib-in-advanced-solid-tumor-patients-with-a-braf-v600-mutation 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06868095/protocolo-de-estudio-multicentrico-impacto-de-la-sarcopenia-en-el-cancer-colorrectal-de-inicio-temprano 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06868095/multi-center-study-protocol-impact-of-sarcopenia-in-early-onset-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06179602/estudio-de-cohorte-prospectivo-sobre-la-ablacion-termica-de-tumores-hepaticos-malignos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/prospective-cohort-study-on-thermal-ablation-of-malignant-liver-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/quimioterapia-neoadyuvante-con-inhibidores-de-pd-1-combinada-con-sib-imrt-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/neoadjuvant-chemotherapy-with-pd-1-inhibitors-combined-with-sib-imrt-in-the-treatment-of-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03711110/estrategias-de-prevencion-cardiovascular-en-pacientes-oncologicos-de-edad-avanzada-ensayo-clinico-cartier 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03711110/cardiovascular-prevention-strategies-in-elderly-patients-with-cancer-cartier-clinical-trial 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04512937/cirugia-asistida-por-navegacion-computarizada-para-el-cancer-colorrectal-localmente-avanzado-y-recurrente 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/computer-navigation-assisted-surgery-for-locally-advanced-and-recurrent-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/quimioterapia-neoadyuvante-con-mfolfox6-combinada-con-terapia-anti-pd-1-en-cancer-colorrectal-localmente-avanzado-mss-pmmr-estudio-firm02 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381400/neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-mss-pmmr-locally-advanced-rectal-cancer-firm02-study 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT00722228/vacuna-contra-el-cancer-con-celulas-tumorales-completas-tanto-autologa-como-alogenica-para-tumores-metastasicos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/autologous-and-allogeneic-whole-cell-cancer-vaccine-for-metastatic-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06496919/investigacion-en-el-mundo-real-sobre-la-prevencion-y-el-tratamiento-de-la-metastasis-peritoneal-y-la-ascitis-maligna-mediante-la-infusion-intraperitoneal-de-rmhtnf-en-tumores-malignos-gastricos-y 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06496919/a-real-world-research-on-the-prevention-and-treatment-of-peritoneal-metastasis-and-malignant-ascites-by-intraperitoneal-infusion-of-rmhtnf-in-gastric-and-colorectal-malignant-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/inyeccion-de-adebrelimab-pd-l1-combinada-con-radioterapia-de-corta-duracion-y-quimioterapia-para-la-terapia-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/adebrelimab-injection-pd-l1-combined-with-short-course-radiotherapy-and-chemotherapy-for-neoadjuvant-therapy-of-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT00843375/evaluacion-de-marcadores-en-heces-para-la-deteccion-temprana-de-cancer-colorrectal-y-adenomas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT00843375/evaluation-of-stool-based-markers-for-the-early-detection-of-colorectal-cancers-and-adenomas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07581912/tratamiento-neoadyuvante-con-fulzerasib-mas-cetuximab-n01-en-cancer-colorrectal-localmente-avanzado-con-mutacion-kras-g12c-con-o-sin-metastasis-resecables 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07581912/neoadjuvant-treatment-of-fulzerasib-plus-cetuximab-n01-in-kras-g12c-mutated-locally-advanced-colorectal-cancer-with-or-without-resectable-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05646511/tnt-de-quimiorradioterapia-qrt-capox-frente-a-qrt-capoxiri-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05646511/tnt-of-scrt-capox-vs-scrt-capoxiri-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07585279/un-estudio-clinico-de-irinotecan-liposomal-para-la-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07585279/a-clinical-study-of-liposomal-irinotecan-for-second-line-therapy-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbioma-y-cancer-de-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbiome-and-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05346757/validacion-de-un-test-fecal-basado-en-microarn-mirfec-para-el-cribado-la-vigilancia-y-el-diagnostico-del-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05346757/validation-of-a-microrna-based-fecal-mirfec-test-for-colorectal-cancer-screening-surveillance-and-diagnosis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03391843/quimioterapia-neoadyuvante-combinada-con-cetuximab-para-el-cancer-colorrectal-localmente-avanzado-con-egfr-de-tipo-salvaje 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/neoadjuvant-chemotherapy-combined-with-cetuximab-for-egfr-wild-type-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06047015/electroforesis-irreversible-nanoknife-r-e-inmunoterapia-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06047015/irreversible-electroporation-nanoknife-r-and-immunotherapy-for-the-treatment-of-stage-iv-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05136326/quimiorradioterapia-preoperatoria-con-capecitabina-y-temozolomida-en-cancer-colorrectal-localmente-avanzado-con-expresion-de-mgmt-silenciada-y-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/preoperative-chemoradiotherapy-with-capecitabine-and-temozolomide-in-mgmt-silenced-mss-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-en-combinacion-con-regorafenib-como-tratamiento-de-tercera-linea-en-pacientes-con-crlm-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06455254/cadonilimab-combined-with-regorafenib-as-a-third-line-treatment-in-patients-with-mss-crlm 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07133750/pm8002-bnt327-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06259552/un-estudio-de-spx-303-un-anticuerpo-bispecifico-dirigido-contra-lilrb2-y-pd-l1-en-pacientes-con-tumores-solidos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/a-study-of-spx-303-a-bispecific-antibody-targeting-lilrb2-and-pd-l1-in-patients-with-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/estudio-para-evaluar-el-uso-de-capecitabina-en-monoterapia-y-en-combinacion-con-oxaliplatino-en-pacientes-ancianos-como-quimioterapia-adyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06888843/study-to-evaluate-the-use-of-capecitabine-in-monotherapy-and-in-combination-with-oxaliplatin-in-elderly-patients-as-adjuvant-chemotherapy-for-locally-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07413146/quimioterapia-neoadyuvante-con-capeox-frente-a-cirugia-inicial-en-cancer-colorrectal-localmente-avanzado-con-niveles-elevados-de-cea-un-ensayo-clinico-aleatorizado-abierto-y-de-un-solo-centro 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/neoadjuvant-capeox-versus-upfront-surgery-for-locally-advanced-colon-cancer-with-elevated-cea-a-single-center-open-label-randomized-controlled-trial 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-junto-con-capox-y-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-mss-un-estudio-aleatorizado-prospectivo-y-multicentrico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/node-sparing-short-course-radiation-with-capox-and-sintilimab-for-mss-locally-advanced-colon-cancer-a-randomized-prospective-multicenter-study 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04715633/inhibidores-de-pd-1-combinados-con-inhibidores-de-vegf-para-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04715633/pd-1-inhibitors-combined-with-vegf-inhibitors-for-locally-advanced-dmmr-msi-h-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06657222/primer-estudio-en-humanos-de-tub-030-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06657222/first-in-human-study-of-tub-030-in-patients-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207981/estudio-de-fase-iii-que-evalua-la-quimioterapia-de-induccion-seguida-de-quimiorradioterapia-en-comparacion-con-la-quimiorradioterapia-estandar-para-el-carcinoma-de-celulas-escamosas-localmente 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207981/phase-iii-study-evaluating-induction-chemotherapy-followed-by-chemoradiotherapy-compared-to-standard-chemoradiotherapy-for-locally-advanced-scca 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985109/kn-046-regorafenib-mas-otro-tratamiento-en-cancer-colorrectal-metastasico-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985109/kn-046-plus-regorafenib-in-mss-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06078670/inhibidor-de-parp-cvl218-en-terapia-combinada-para-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06078670/parp-inhibitor-cvl218-in-combination-therapy-for-patients-with-advanced-solid-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/combinacion-triple-o-regimen-de-doble-farmaco-frente-a-quimiorradiacion-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/triplet-combination-or-doublet-regimen-versus-chemoradiation-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-antes-de-la-cirugia-para-el-tratamiento-del-cancer-colorrectal-her2-positivo-en-pacientes-candidatos-a-tratamiento-con-intencion-curativa 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-before-surgery-for-the-treatment-of-her2-positive-colon-and-rectal-cancer-in-patients-planned-for-curative-intent-treatment 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553234/estudio-para-comprender-la-relacion-entre-la-salud-intestinal-y-las-toxicidades-del-tratamiento-hormonal-del-cancer-de-mama 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/study-to-understand-relationship-between-gut-health-and-toxicities-of-hormonal-breast-cancer-treatment 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/revision-del-protocolo-para-el-tratamiento-del-cancer-colorrectal-en-atencion-secundaria 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/secondary-care-colorectal-cancer-pathway-review 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotido-acetato-e-interferon-alfa-2b-recombinante-o-bevacizumab-en-el-tratamiento-de-pacientes-con-tumor-neuroendocrino-metastasico-o-localmente-avanzado-de-alto-riesgo 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotide-acetate-and-recombinant-interferon-alfa-2b-or-bevacizumab-in-treating-patients-with-metastatic-or-locally-advanced-high-risk-neuroendocrine-tumor 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07172282/infinitive-inmunoterapia-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-immunotherapy-for-patients-with-colorectal-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06792695/un-estudio-de-nuevas-intervenciones-y-combinaciones-terapeuticas-en-participantes-con-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06792695/a-study-of-novel-study-interventions-and-combinations-in-participants-with-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/un-programa-de-manejo-intestinal-enema-rectal-retrogrado-para-el-tratamiento-del-sindrome-de-reseccion-anterior-baja-en-pacientes-con-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06714903/efecto-de-la-microbiota-intestinal-y-sus-metabolitos-en-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06642844/quimioterapia-basada-en-bevacizumab-adaptada-a-la-farmacocinetica-del-bevacizumab-en-el-tratamiento-de-primera-linea 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06642844/bevacizumab-based-chemotherapy-adapted-to-bevacizumab-pharmacokinetics-in-1st-line-treatment 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843434/un-estudio-de-botensilimab-y-balstilimab-para-el-adenocarcinoma-rectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843434/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinoma 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06443671/fruquintinib-neoadyuvante-mas-tislelizumab-en-combinacion-con-mcapeox-frente-a-capeox-para-el-cancer-colorrectal-localmente-avanzado-de-pmmr-mss-intermedio-alto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/neoadjuvant-fruquintinib-plus-tislelizumab-combined-with-mcapeox-versus-capeox-for-mid-high-pmmr-mss-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06640049/un-estudio-de-dostarlimab-en-participantes-con-cancer-colorrectal-localmente-avanzado-no-tratado-en-china 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/a-study-of-dostarlimab-in-participants-with-untreated-locally-advanced-rectal-cancer-in-china 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07220174/uso-del-software-gi-genius-tm-xr-en-un-visor-de-realidad-virtual-durante-una-colonoscopia-de-rutina 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07220174/use-of-gi-genius-tm-xr-software-in-virtual-reality-headset-during-routine-colonoscopy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02113384/cancer-colorrectal-localmente-avanzado-celulas-tumorales-exfoliadas-del-peritoneo 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02113384/locally-advanced-rectal-cancer-exfoliated-peritoneal-tumor-cells 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/deteccion-de-metastasis-cerebrales-mediante-resonancia-magnetica-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/detection-of-brain-metastasis-by-mri-in-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06946615/estudio-clinico-exploratorio-de-terapia-car-dc-y-car-t-dirigida-contra-claudin18-2-en-cancer-colorrectal-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06946615/exploratory-clinical-study-of-claudin18-2-targeted-car-dc-and-car-t-therapy-in-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03921684/ensayo-clinico-de-nivolumab-en-combinacion-con-folfox-tras-quimiorradioterapia-en-pacientes-con-cancer-de-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03921684/trial-of-nivolumab-with-folfox-after-chemoradiation-in-rectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05025826/estudio-que-evalua-la-neurotoxicidad-en-pacientes-con-cancer-gastrointestinal-metastasico-que-reciben-phycocare-r-o-placebo-durante-la-quimioterapia-basada-en-oxaliplatino 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05025826/study-evaluating-neurotoxicity-in-patients-with-metastatic-gastro-intestinal-cancer-taking-phycocare-r-or-placebo-during-oxaliplatin-based-chemotherapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/quimioembolizacion-lifepearls-irinotecan-en-pacientes-con-cancer-colorrectal-y-enfermedad-metastasica 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595266/chemoembolization-lifepearls-irinotecan-in-patients-with-colorectal-cancer-and-metastatic-disease 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06965166/tomografia-computarizada-con-detector-de-fotones-de-conteo-y-contraste-pcd-ct-para-la-estadificacion-local-del-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/contrast-enhanced-photon-counting-detector-ct-pcd-ct-for-the-local-staging-of-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06253520/celulas-t-autologas-modificadas-geneticamente-para-expresar-receptores-reactivos-contra-las-mutaciones-de-kras-en-combinacion-con-una-vacuna-dirigida-contra-estos-antigenos-en-participantes-con 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06253520/autologous-t-cells-genetically-engineered-to-express-receptors-reactive-against-kras-mutations-in-conjunction-with-a-vaccine-directed-against-these-antigens-in-participants-with-metastatic-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07202364/un-estudio-de-yl202-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/a-study-of-yl202-in-patients-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/estudio-que-evalua-el-tratamiento-personalizado-del-carcinoma-rectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04867525/plataforma-de-registro-de-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04867525/registry-platform-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06638502/seguridad-de-hrx215-en-pacientes-despues-de-una-reseccion-hepatica-menor-o-mayor 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06638502/safety-of-hrx215-in-patients-after-minor-and-major-liver-resection 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-nuevas-terapias-oncologicas-en-combinacion-con-quimioterapia-y-bevacizumab-como-terapia-de-primera-linea-en-el-crc-mss 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04068610/columbia-1-novel-oncology-therapies-in-combination-with-chemotherapy-and-bevacizumab-as-first-line-therapy-in-mss-crc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04291105/ensayo-de-fase-ii-de-voyager-v1-en-combinacion-con-cemiplimab-en-pacientes-con-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04291105/phase-2-trial-of-voyager-v1-in-combination-with-cemiplimab-in-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/cannabis-medicinal-en-pacientes-con-cancer-avanzado-de-pancreas-y-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06577194/un-estudio-de-un-solo-centro-de-un-solo-brazo-sobre-radioterapia-neoadyuvante-de-curso-corto-con-il-2-seguida-de-inmunoterapia-secuencial-con-capox-combinada-con-un-anticuerpo-anti-pd-1-e-il-2-para 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06577194/a-single-center-single-arm-study-of-neoadjuvant-short-course-radiotherapy-with-il-2-followed-by-sequential-immunotherapy-with-capox-combined-with-pd-1-antibody-and-il-2-for-locally-advanced-rectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/investigacion-genomica-de-pacientes-con-respuestas-inusuales 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/genomic-investigation-of-unusual-responders 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06788171/pulsar-en-combinacion-con-un-anticuerpo-anti-pd-1-y-quimioterapia-mas-bevacizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-ccrm 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06788171/pulsar-combined-with-pd-1-ab-and-chemotherapy-plus-bev-for-crlm 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07085091/un-estudio-de-fase-i-en-humanos-con-alx2004-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-seleccionados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06507371/radioterapia-de-curso-corto-que-preserva-los-ganglios-combinada-con-capox-y-tislelizumab-para-el-cancer-colorrectal-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06507371/node-sparing-short-course-radiation-combined-with-capox-and-tislelizumab-for-mss-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/folfoxiri-modificado-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-un-estudio-prospectivo-de-fase-ii 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/modified-folfoxiri-plus-target-therapy-as-a-first-line-treatment-for-advanced-colorectal-cancer-a-prospective-phase-two-study 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06896162/progreso-oncologia-de-precision-mediante-evaluaciones-genomicas-reflexivas-para-la-seleccion-de-estudios-y-la-supervivencia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06896162/progress-precision-oncology-using-genomic-reflexive-evaluations-for-study-selection-and-survival 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/un-estudio-de-investigacion-anticuerpo-m5a-marcado-con-64cu-en-combinacion-con-quimioterapia-y-radioterapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05245786/an-investigational-scan-64cu-labeled-m5a-antibody-in-combination-with-soc-chemotherapy-and-radiotherapy-in-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-en-combinacion-con-trifluridina-tipiracil-frente-a-bevacizumab-en-combinacion-con-trifluridina-tipiracil-para-el-cancer-colorrectal-metastasico-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07286695/fruquintinib-combined-with-trifluridine-tipiracil-versus-bevacizumab-combined-with-trifluridine-tipiracil-for-advanced-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05605353/aprovechando-el-potencial-del-microbioma-intestinal-y-sus-metabolitos-en-el-cancer-pelvico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05605353/exploiting-the-gut-microbiota-and-its-metabolites-in-pelvic-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05967143/estudio-observacional-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-irresecables-registro-sirtain 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05967143/observational-sir-spheres-study-for-the-treatment-of-unresectable-liver-tumors-sirtain-registry 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04258137/adn-circulante-para-mejorar-el-pronostico-de-los-pacientes-oncologicos-un-estudio-aleatorizado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04258137/circulating-dna-to-improve-outcome-of-oncology-patient-a-randomized-study 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05539677/biobanco-y-registro-de-pacientes-con-tumores-agresivos-para-la-investigacion-traslacional-y-analitica 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05539677/biobank-and-register-of-patients-with-agresive-tumors-for-translational-and-analytical-research 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/quimioterapia-folfox-preoperatoria-frente-a-quimioterapia-postoperatoria-adaptada-al-riesgo-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04495088/preoperative-folfox-versus-postoperative-risk-adapted-chemotherapy-in-patients-with-locally-advanced-rectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT01918527/quimioterapia-neoadyuvante-frente-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/neoadjuvant-chemotherapy-versus-standard-treatment-in-patients-with-locally-advanced-colon-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/quimioterapia-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-a-quimioterapia-neoadyuvante-con-capox-folfox-y-quimiorradioterapia-seguida-de-cirugia-o-una-estrategia-de-observacion-activa-en 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-followed-by-surgery-or-a-watch-and-wait-approach-in-high-risk-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/utilizando-bacterias-beneficiosas-del-intestino-para-potenciar-el-tratamiento-inmunologico-del-cancer-colorrectal-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07486492/using-healthy-gut-bacteria-to-boost-immune-treatment-for-advanced-bowel-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06563388/radioterapia-ablativa-estereotactica-sabr-para-el-tratamiento-de-pacientes-con-cancer-metastasico-ensayo-id-comet 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/ensayo-collision-relapse 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05861505/collision-relapse-trial 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/deteccion-de-metastasis-sincronicas-en-el-cancer-colorrectal-mediante-resonancia-magnetica-con-difusion-serenade 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06464692/estudio-para-evaluar-los-eventos-adversos-y-como-el-telisotuzumab-adizutecan-abbv-400-administrado-por-via-intravenosa-iv-se-distribuye-por-el-organismo-de-los-participantes-adultos-con-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06464692/study-to-assess-adverse-events-and-how-intravenously-iv-infused-telisotuzumab-adizutecan-abbv-400-moves-through-the-body-of-adult-participants-with-unresectable-locally-advanced-metastatic-colorectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06826092/metformina-para-el-tratamiento-de-pacientes-con-mcrc-que-reciben-folfiri-mas-terapia-dirigida 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07502014/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-fruquintinib-y-radioterapia-heterogenea-en-comparacion-con-fruquintinib-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07502014/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-fruquintinib-and-heterogeneous-radiotherapy-versus-fruquintinib-as-third-line-and-subsequent-line-treatment-for-metastatic-colorectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03776591/colecolectomia-derecha-abierta-versus-colecolectomia-minimamente-invasiva-laparoscopica-para-el-cancer-de-colon-derecho 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/open-d3-right-hemicolectomy-compared-to-laparoscopic-cme-for-right-sided-colon-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/un-estudio-prospectivo-de-cancer-colorrectal-metastasico-de-tipo-mss-que-recibe-multiples-lineas-de-quimioterapia-estandar-bevacizumab-en-combinacion-con-adebrelimab 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/a-prospective-study-of-mss-type-metastatic-colorectal-cancer-receiving-multiple-lines-of-standard-chemotherapy-bevacizumab-combined-with-adebrelimab 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07114601/un-estudio-de-ly4257496-en-participantes-con-cancer-omniray 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/a-study-of-ly4257496-in-participants-with-cancer-omniray 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/estudio-de-ide196-en-pacientes-con-tumores-solidos-que-presentan-mutaciones-en-gnaq-11-o-fusiones-en-prkc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/study-of-ide196-in-patients-with-solid-tumors-harboring-gnaq-11-mutations-or-prkc-fusions 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959693/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-envafolimab-en-combinacion-con-cetuximab-y-mfolfox6-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-mss-y-ras-braf-de-tipo-salvaje 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959693/a-clinical-study-to-evaluate-the-efficacy-and-safety-of-envafolimab-combined-with-cetuxima-and-mfolfox6-in-patients-with-mss-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07506109/un-estudio-de-fase-ii-de-sintilimab-en-combinacion-con-ipilimumab-n01-cetuximab-y-dabrafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables-y-mutacion-braf-v600e 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07506109/a-phase-ii-study-of-sintilimab-combined-with-ipilimumab-n01-cetuximab-and-dabrafenib-in-patients-with-microsatellite-stable-braf-v600e-mutated-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/estudio-de-fase-ii-de-emb-01-en-pacientes-con-cancer-colorrectal-recurrente-o-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/phase-ii-study-of-emb-01-in-recurrent-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/estudio-de-fase-ii-de-sr-8541a-en-combinacion-con-botensilimab-y-balstilimab-en-sujetos-con-cancer-colorrectal-metastasico-resistente-al-tratamiento-y-con-estabilidad-de-microsatelites-mss-crc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-balstilimab-in-subjects-with-refractory-metastatic-microsatellite-stable-colorectal-cancer-mss-crc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06750094/un-estudio-de-amivantamab-y-folfiri-frente-a-cetuximab-bevacizumab-y-folfiri-en-participantes-con-cancer-colorrectal-kras-nras-y-braf-de-tipo-salvaje-que-previamente-han-recibido-quimioterapia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06750094/a-study-of-amivantamab-and-folfiri-versus-cetuximab-bevacizumab-and-folfiri-in-participants-with-kras-nras-and-braf-wild-type-colorectal-cancer-who-have-previously-received-chemotherapy 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07515963/fuliri-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-la-terapia-de-conversion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-plus-targeted-therapy-for-first-line-conversion-therapy-of-colorectal-cancer-liver-metastases 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07257653/seguridad-y-eficacia-de-cetuximab-beta-mas-fruquintinib-con-o-sin-inhibidores-de-los-puntos-de-control-inmunitario-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/the-safety-and-efficacy-of-cetuximab-beta-plus-fruquintinib-with-or-without-immune-checkpoint-inhibitorrs-in-first-line-treatment-of-ras-braf-wild-type-unresectable-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06699836/ensayo-de-fase-ii-clover-que-evalua-el-uso-de-leronlimab-un-farmaco-dirigido-al-ccr5-en-combinacion-con-quimioterapia-oral-y-un-regimen-enriquecido-con-un-inhibidor-del-vegf 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06699836/the-phase-2-ccr5-targeting-leronlimab-with-oral-chemotherapy-and-vegf-inhibitor-enriched-regimen-trial-clover 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/evaluacion-del-farmaco-antitumoral-rogaratinib-bay-1163877-para-el-tratamiento-del-sarcoma-avanzado-con-alteracion-en-el-receptor-del-factor-de-crecimiento-de-fibroblastos-fgfr-1-4-y-en-pacientes-con 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04595747/testing-the-anti-cancer-drug-rogaratinib-bay-1163877-for-treatment-of-advanced-sarcoma-with-alteration-in-fibroblast-growth-factor-receptor-fgfr-1-4-and-in-patients-with-sdh-deficient 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/evaluacion-de-agentes-dirigidos-en-canceres-digestivos-en-china-basada-en-las-caracteristicas-moleculares 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04584008/targeted-agent-evaluation-in-digestive-cancers-in-china-based-on-molecular-characteristics 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06749015/un-estudio-sobre-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-brafv600e 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06749015/a-study-on-treatment-for-patients-with-brafv600e-mutant-metastatic-colorectal-cancer-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/un-estudio-para-evaluar-el-uso-de-telisotuzumab-adizutecan-intravenoso-iv-en-combinacion-con-bevacizumab-iv-en-comparacion-con-el-tratamiento-estandar-con-bevacizumab-iv-en-combinacion-con 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07525206/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-iv-bevacizumab-compared-to-standard-of-care-iv-bevacizumabin-combination-with-oral-trifluridine-and-tipiracil-in-adult 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05746897/un-estudio-de-fase-i-abierto-multicentrico-y-de-primera-administracion-en-humanos-de-nm1f-anti-pvrig-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05746897/a-first-in-human-phase-i-open-label-multicenter-study-of-nm1f-anti-pvrig-in-patients-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/trasplante-hepatico-en-comparacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/liver-transplantation-compared-to-chemotherapy-in-patients-with-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparacion-de-la-eficacia-y-la-seguridad-entre-folfox-6-y-capox-en-el-carcinoma-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07334587/comparison-of-efficacy-and-safety-between-folfox-6-and-capox-in-metastatic-colorectal-carcinoma 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-para-el-tratamiento-de-cancer-colorrectal-localmente-avanzado-irresecable-y-no-metastasico-con-dmmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05131919/pembrolizumab-for-locally-advanced-irresectable-non-metastatic-dmmr-colorectal-cancers 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/estudio-de-fruquintinib-en-combinacion-con-tegafur-gimeracil-y-oteracil-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06395519/un-estudio-del-inhibidor-de-parg-etx-19477-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/a-study-of-parg-inhibitor-etx-19477-in-patients-with-advanced-solid-malignancies 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/estudio-de-ivx037-administrado-intratumoralmente-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/study-of-intratumoral-ivx037-in-patients-with-advanced-or-metastatic-solid-tumours 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614192/un-estudio-que-evalua-los-eventos-adversos-y-la-actividad-de-la-enfermedad-al-comparar-la-administracion-intravenosa-iv-de-abbv-400-con-los-comprimidos-orales-de-trifluridina-y-tipiracil-lonsurf-mas 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/a-study-assessing-adverse-events-and-disease-activity-of-intravenously-iv-infused-telisotuzumab-adizutecan-in-adult-participants-with-c-met-protein-above-cutoff-level-above-refractory-metastatic 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06678919/registro-agmt-de-cancer-colorrectal-metastasico-mcrc-en-tercera-linea-de-tratamiento-y-posteriores 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/agmt-metastatic-colorectal-cancer-registry-mcrc-third-line-and-beyond 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/efecto-del-ancho-del-margen-quirurgico-en-la-recurrencia-y-la-supervivencia-en-pacientes-con-oligometastasis-hepatica-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934018/effect-of-surgical-margin-width-on-recurrence-and-survival-in-patients-with-hepatic-oligometastasis-of-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04224779/biopsias-liquidas-e-imagenologia-para-mejorar-la-atencion-oncologica 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/liquid-biopsies-and-imaging-for-improved-cancer-care 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03867799/iscore-secuenciacion-de-la-inmunoterapia-en-el-cancer-de-colon-y-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03867799/iscore-immunotherapy-sequencing-in-colon-and-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449937/tratamiento-local-hepatico-para-metastasis-de-cancer-colorrectal-multiorganico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/local-liver-treatment-for-multi-organ-colorectal-cancer-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201352/evaluacion-de-la-eficacia-de-trifluridina-tipiracil-mas-un-anticuerpo-humano-verdadero-anti-il-1-frente-a-trifluridina-tipiracil-mas-placebo-en-pacientes-con-cancer-colorrectal-metastasico-despues 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201352/evaluation-of-efficacy-of-trifluridine-tipiracil-plus-an-anti-il-1-true-human-antibody-versus-trifluridine-tipiracil-plus-placebo-in-metastatic-colorectal-cancer-patients-after-failure-of-oxaliplatin 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06012734/lb-100-inhibidor-de-pp2a-y-atezolizumab-inhibidor-de-pd-l1-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06012734/lb-100-pp2a-inhibitor-and-atezolizumab-pd-l1-inhibitor-in-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/evaluacion-de-la-eficacia-y-la-seguridad-de-la-seleccion-basada-en-el-adn-tumoral-circulante-ctdna-para-un-nuevo-tratamiento-con-anti-egfr-en-una-cohorte-de-pacientes-con-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05652894/un-estudio-de-hx008-en-comparacion-con-la-quimioterapia-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-metastasico-msi-h-dmmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/a-study-of-hx008-compared-to-chemotherapy-in-the-first-line-treatment-of-subjects-with-msi-h-dmmr-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-en-pacientes-con-tumores-solidos-metastasicos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT01815359/icarus-quimioterapia-intraperitoneal-postoperatoria-epic-y-quimioterapia-intraperitoneal-hiperermica-hipec-tras-una-cirugia-citoreductora-optima-crs-para-neoplasias-del-apendice-colon-o-recto-con 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT01815359/icarus-post-operative-intraperitoneal-chemotherapy-epic-and-hyperthermic-intraperitoneal-chemotherapy-hipec-after-optimal-cytoreductive-surgery-crs-for-neoplasms-of-the-appendix-colon-or-rectum-with 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/un-estudio-de-fase-i-multicentrico-aleatorizado-doble-ciego-y-controlado-en-paralelo-que-compara-hlx05-n-con-erbitux-r-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/a-phase-i-multicentre-randomized-double-blind-parallel-controlled-study-of-hlx05-n-vs-erbitux-r-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05755672/biomarcadores-durante-el-tratamiento-en-el-cancer-colorrectal-metastasico-para-mejorar-la-calidad-de-vida 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05755672/on-treatment-biomarkers-in-metastatic-colorectal-cancer-for-life 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06849362/estudio-retrospectivo-multicentrico-sobre-la-optimizacion-de-las-estrategias-de-inmunoterapia-combinada-en-el-cancer-colorrectal-avanzado-mss-msi-l-pmmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06849362/multicenter-retrospective-study-on-optimizing-combination-immunotherapy-strategies-in-mss-msi-l-pmmr-advanced-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07154173/analisis-exhaustivo-de-las-caracteristicas-de-la-microbiota-intestinal-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154173/comprehensive-analysis-of-gut-microbiota-signatures-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05129787/ablacion-frente-a-reseccion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129787/ablation-vs-resection-of-colorectal-cancer-liver-metastases 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03526835/un-estudio-del-anticuerpo-bispecifico-mcla-158-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03526835/a-study-of-bispecific-antibody-mcla-158-in-patients-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07271355/quimioterapia-intraabdominal-en-aerosol-a-presion-con-mitomicina-para-el-tratamiento-del-cancer-de-apendice-o-de-colon-recto-irresecable-con-metastasis-peritoneales-el-ensayo-impact 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/pressurized-intraperitoneal-aerosolized-chemotherapy-with-mitomycin-for-the-treatment-of-unresectable-appendix-or-colorectal-cancer-with-peritoneal-metastases-the-impact-trial 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05775146/radioterapia-estereotactica-ablativa-sbrt-de-metastasis-tras-el-tratamiento-neoadyuvante-para-el-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/sbrt-of-metastases-following-neo-adjuvant-treatment-for-colorectal-cancer-with-synchronous-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabina-y-atezolizumab-para-el-cancer-colorrectal-oligo-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-y-pirfenidona-en-combinacion-con-un-anticuerpo-anti-pd-1-en-el-tratamiento-del-carcinoma-colorrectal-avanzado-o-metastasico-pmmr-mss 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06484153/fruquintinib-and-pirfenidone-in-combination-with-anti-pd-1-antibody-in-advanced-or-metastatic-pmmr-mss-colorectal-carcinoma 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06411600/terapia-combinada-para-el-crcm-metastasico-con-mutacion-braf-v600e 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06411600/combination-therapy-for-braf-v600e-metastatic-crcm 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07551778/terapia-con-celulas-nk-alogenicas-combinada-con-el-tratamiento-de-mantenimiento-estandar-en-tumores-solidos-avanzados 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07551778/allogeneic-nk-cell-therapy-combined-with-standard-maintenance-treatment-in-advanced-solid-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-tercera-linea-o-posterior-en-pacientes-con-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06403709/irinotecan-tas-102-plus-bevacizumab-as-a-third-line-or-beyond-therapy-in-mcrc-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06485713/eficacia-y-seguridad-de-la-combinacion-de-trifluridina-tipiracil-con-fufuquitinib-como-tratamiento-de-tercera-linea-para-el-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06485713/efficacy-and-safety-of-trifluridine-tipiracil-combined-with-fufuquitinib-for-third-line-treatment-of-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06521827/el-papel-de-un-ciclo-corto-de-radioterapia-paliativa-en-el-cancer-de-recto-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06521827/the-role-of-short-course-of-palliative-radiation-in-metastatic-cancer-rectum 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07559760/nueva-terapia-combinada-de-segunda-linea-para-el-cancer-colorrectal-metastasico-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07559760/new-second-line-combo-therapy-for-mss-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07061210/un-estudio-exploratorio-de-hrs-2189-en-combinacion-con-adebrelimab-y-bp102-para-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07061210/an-explorative-study-of-hrs-2189-combined-with-adebrelimab-and-bp102-for-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/estudio-sobre-la-prediccion-de-metastasis-en-los-ganglios-linfaticos-regionales-en-el-cancer-colorrectal-mediante-tomografia-computarizada-espectral-combinada-con-msi 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/study-on-the-prediction-of-regional-lymph-node-metastasis-in-colorectal-cancer-by-spectral-ct-combined-with-msi 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/estudio-comparativo-de-mitomicina-y-lobaplatino-en-pacientes-con-cancer-colorrectal-avanzado-sometidos-a-cirugia-radical-combinada-con-quimioterapia-intraperitoneal-hiperermica 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224815/biomarcadores-de-cfdna-5mc-5hmc-para-predecir-la-respuesta-a-la-quimioterapia-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224815/cfdna-5mc-5hmc-biomarkers-to-predict-chemotherapy-response-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/estudio-ice-combinacion-de-irinotecan-mas-cetuximab-y-envafolimab-como-regimen-de-retreatment-en-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-en-combinacion-con-quimioterapia-metronomica-multimodal-para-cancer-colorrectal-metastasico-resistente-a-la-quimioterapia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-in-combination-with-multimodal-metronomic-chemotherapy-for-chemo-resistant-metastatic-colorectal-cancers 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/estudio-clinico-del-tratamiento-de-segunda-linea-en-el-cancer-colorrectal-avanzado-con-quimioterapia-con-bevacizumab-o-cetuximab 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540326/clinical-study-of-second-line-treatment-in-advanced-colorectal-cancer-with-chemotherapy-with-bevacizumab-or-cetuximab 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03428477/epa-para-el-ensayo-clinico-sobre-metastasis-2 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03428477/epa-for-metastasis-trial-2 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07389265/continuacion-del-tratamiento-con-cetuximab-tras-la-progresion-en-primera-linea-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06833866/ensayo-de-fase-i-de-una-terapia-basada-en-5-fluorouracilo-5fu-en-combinacion-con-hidroxitirosol-ht-en-pacientes-con-cancer-colorrectal-avanzado-o-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06833866/phase-i-trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-hydroxytyrosol-ht-in-patients-with-advanced-or-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT01792934/quimioterapia-y-reseccion-quirurgica-maxima-de-las-metastasis-de-cancer-colorrectal-multiorganico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT01792934/chemotherapy-and-maximal-tumor-debulking-of-multi-organ-colorectal-cancer-metastases 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06208397/resonancia-magnetica-para-la-evaluacion-de-los-patrones-de-crecimiento-histopatologicos-en-metastasis-hepaticas-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06208397/mre-for-assessment-of-histopathological-growth-patterns-in-colorectal-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07395063/un-estudio-clinico-sobre-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/biopsia-liquida-centrada-en-las-celulas-tumorales-circulantes-y-el-adn-tumoral-circulante-como-herramienta-de-medicina-de-precision-en-los-tumores-gastrointestinales 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/liquid-biopsy-focusing-on-circulating-tumor-cells-and-circulating-tumor-dna-as-precision-medicine-in-gastrointestinal-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06714357/acido-valproico-para-potenciar-la-eficacia-del-tratamiento-anti-egfr-y-prevenir-revertir-la-resistencia-en-el-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714357/valproic-acid-to-potentiate-anti-egfr-treatment-efficacy-and-prevent-revert-resistance-in-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-68ga-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-en-combinacion-con-terapia-de-mantenimiento-para-la-prevencion-de-la-recurrencia-postoperatoria-en-cancer-colorrectal-con-metastasis-peritoneales 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07405736/lubiprostone-combined-with-maintenance-therapy-for-prevention-of-postoperative-recurrence-in-peritoneal-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04547166/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-serplulimab-hlx10-en-combinacion-con-bevacizumab-hlx04-y-quimioterapia-xelox-en-pacientes-con-cancer-colorrectal-metastasico-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04547166/a-clinical-study-to-evaluate-efficacy-and-safety-of-serplulimab-hlx10-combined-with-bevacizumab-hlx04-and-chemotherapy-xelox-in-patients-with-metastatic-colorectal-cancer-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509880/inmunovigilancia-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06509880/immunosurveillance-for-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06148402/fruquintinib-mas-camrelizumab-y-capecitabina-como-terapia-de-rescate-tras-la-progresion-con-un-tratamiento-de-primera-linea-basado-en-folfoxiri-en-pacientes-con-cancer-colorrectal-irresecable 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06148402/fruquintinib-plus-camrelizumab-and-capecitabine-as-salvage-therapy-after-progression-on-folfoxiri-based-first-line-treatment-in-patients-with-unresectable-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05354674/firma-de-aprendizaje-profundo-multimodal-para-la-evaluacion-de-la-respuesta-al-bevacizumab-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/multimodal-deep-learning-signature-for-evaluation-of-response-to-bevacizumab-in-patient-with-colorectal-cancer-liver-metastasis 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparacion-de-la-hepatectomia-y-la-ablacion-local-para-el-tratamiento-de-metastasis-hepaticas-sincronicas-y-metacronicas-resecables-del-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02886104/comparison-of-hepatectomy-and-local-ablation-for-resectable-synchronous-and-metachronous-colorectal-liver-metastasis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05655780/el-papel-del-perfil-molecular-tumoral-cms-el-genotipo-ugt1a1-y-la-actividad-de-la-beta-glucuronidasa-de-la-microbiota-intestinal-en-la-eficacia-del-tratamiento-la-toxicidad-la-supervivencia-y-la 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05655780/the-role-of-the-tumor-molecular-profile-cms-ugt1a1-genotype-and-beta-glucuronidase-activity-of-the-intestinal-microbiota-for-treatment-efficiency-toxicity-survival-and-quality-of-life-in-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02597348/trasplante-hepatico-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-tratados-con-quimioterapia 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02597348/liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases-treated-by-chemotherapy 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-en-combinacion-con-bevacizumab-y-el-regimen-folfox-para-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-avanzado-irresecable-y-de-tipo-mss-con-mutacion-en-los-genes-ras 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-in-combination-with-bevacizumab-and-folfox-regimen-for-the-first-line-treatment-of-advanced-unresectable-mss-type-ras-mutated-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05243862/seguridad-y-actividad-de-polypepi1018-en-combinacion-con-atezolizumab-en-el-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05243862/safety-and-activity-of-polypepi1018-plus-atezolizumab-in-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/producto-microbiano-para-promover-la-salud-del-microbioma-y-mejorar-la-administracion-de-la-quimioterapia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05296681/microbiotic-product-to-promote-microbiome-health-and-improve-chemotherapy-delivery 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05579340/ejercicio-fisico-postoperatorio-y-metastasis-hepatica-del-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/postoperative-exercise-training-and-colorectal-cancer-liver-metastasis 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-solo-o-en-combinacion-con-radioterapia-hipofraccionada-de-baja-dosis-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05963490/regorafenib-alone-or-in-combination-with-hypofractionated-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/un-estudio-de-gsk5764227-en-combinacion-con-el-tratamiento-estandar-soc-u-otros-agentes-en-participantes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07000305/un-estudio-de-cetuximab-combinado-con-envolimab-y-mfolfox6-en-sujetos-con-cancer-colorrectal-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/a-study-of-cetuximab-combined-with-envolimab-and-mfolfox6-in-subjects-with-advanced-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06630624/determinacion-de-la-dosis-eficacia-y-respuesta-inmunologica-de-ip-001-tras-ablacion-por-microondas-mwa-o-ablacion-por-radiofrecuencia-irreversible-ire-en-pacientes-con-metastasis-hepaticas-de-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/dose-finding-efficacy-and-immunological-response-of-ip-001-following-mwa-or-ire-for-crlm 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05022030/mcapox-cetuximab-frente-a-mfolfox6-cetuximab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-del-lado-izquierdo-con-genes-ras-braf-de-tipo-salvaje 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05022030/first-line-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-metastatic-left-sided-crc-with-wild-type-ras-braf-genes 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06935149/deteccion-del-cancer-colorrectal-con-lesiones-metastasicas-en-el-higado-mediante-el-uso-de-nuevas-herramientas-de-imagenologia-de-alta-precision 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06935149/detecting-colorectal-cancer-with-liver-metastatic-lesions-using-novel-precise-imaging-tools 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/desescalada-o-cambio-de-tratamiento-segun-la-variacion-del-adn-tumoral-circulante-tras-2-ciclos-de-quimioterapia-combinada-mas-terapia-dirigida-en-el-cancer-colorrectal-metastasico-irresecable 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06446557/de-scalation-or-switch-of-treatment-according-to-circulating-tumor-dna-variation-after-2-cycles-of-doublet-chemotherapy-plus-targeted-agent-in-metastatic-unresectable-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/eficacia-y-seguridad-de-ak104-en-combinacion-con-quimioterapia-y-cetuximab-o-bevacizumab 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07253896/efficacy-and-safety-of-ak104-combined-with-chemotherapy-and-cetuximab-or-bevacizumab 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05611034/perfusion-pulmonar-in-vivo-ivlp-para-el-cancer-colorrectal-metastasico-en-pulmon 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/in-vivo-lung-perfusion-ivlp-for-colorectal-cancer-metastatic-to-lung 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-regimen-estandar-de-quimioterapia-e-inmunoterapia-con-celulas-t-receptor-de-antigeno-quimerico-alogenicas-basadas-en-nkg2d-cyad-101 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-standard-chemotherapy-regimen-and-immunotherapy-with-allogeneic-nkg2d-based-cyad-101-chimeric-antigen-receptor-t-cells 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-inoperables-o-tumores-solidos-recurrentes-refractarios 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07189871/177lu-betabart-in-patients-with-relapsed-refractory-locally-advanced-inoperable-or-metastatic-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/estudio-de-dosis-quimioterapia-con-dosis-reducidas-en-primera-linea-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/dosage-study-upfront-dose-reduced-chemotherapy-in-older-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06883084/relevancia-clinica-de-la-regresion-patologica-en-los-ganglios-linfaticos-en-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06883084/clinical-relevance-of-pathologic-regression-in-lymph-node-for-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05240950/celulas-car-t-anti-cea-para-el-tratamiento-de-metastasis-hepaticas-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/anti-cea-car-t-cells-to-treat-colorectal-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854668/un-estudio-de-la-combinacion-de-anlotinib-clorhidrato-en-capsulas-con-quimioterapia-como-tratamiento-de-primera-linea-en-sujetos-con-cancer-colorrectal-metastasico-ras-braf-tipo-salvaje 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854668/a-study-of-anlotinib-hydrochloride-capsule-combined-with-chemotherapy-as-first-line-treatment-in-subjects-with-ras-braf-wild-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201194/acupuntura-holistica-para-pacientes-con-nauseas-inducidas-por-la-quimioterapia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201194/holistic-acupuncture-for-patients-with-chemotherapy-induced-nausea 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/un-estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-fruquintinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-pd-1-y-chidamide-en-el-cancer-colorrectal-metastasico-refractario-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/a-clinical-study-on-the-efficacy-and-safety-of-fruquintinib-in-combination-with-pd-1-monoclonal-antibody-and-chidamide-in-refractory-mss-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/estudio-de-plataforma-sobre-combinaciones-de-inmunoterapia-en-metastasis-hepaticas-del-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06300463/platform-study-of-immunotherapy-combinations-in-colorectal-cancer-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04008030/un-estudio-de-nivolumab-nivolumab-mas-ipilimumab-o-quimioterapia-a-eleccion-del-investigador-para-el-tratamiento-de-participantes-con-cancer-colorrectal-metastasico-mcrc-con-deficiencia-en-la 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/a-study-of-nivolumab-nivolumab-plus-ipilimumab-or-investigator-s-choice-chemotherapy-for-the-treatment-of-participants-with-deficient-mismatch-repair-dmmr-microsatellite-instability-high-msi-h 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150247/seguridad-y-eficacia-de-ib-folfiri-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07150247/safety-and-efficacy-of-ib-folfiri-in-braf-v600e-mutant-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03203525/quimioterapia-combinada-y-bevacizumab-con-el-sistema-novottf-100l-p-en-el-tratamiento-de-participantes-con-cancer-hepatico-metastasico-avanzado-recurrente-o-refractario 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03203525/combination-chemotherapy-and-bevacizumab-with-the-novottf-100l-p-system-in-treating-participants-with-advanced-recurrent-or-refractory-hepatic-metastatic-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05008809/quimioterapia-post-reseccion-ablacion-en-pacientes-con-cancer-colorrectal-metastasico-fire-9-port-aio-krk-0418 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05008809/post-resection-ablation-chemotherapy-in-patients-with-metastatic-colorectal-cancer-fire-9-port-aio-krk-0418 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07070713/eficacia-y-seguridad-de-folfox-cetuximab-frente-a-folfoxiri-bevacizumab-ambos-en-combinacion-con-ql1706-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-mcrc-localizado-en-el 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/efficacy-and-safety-of-folfox-cetuximab-vs-folfoxiri-bevacizumab-both-with-ql1706-in-first-line-treatment-of-left-sided-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparacion-de-la-eficacia-y-la-seguridad-de-enlituo-r-frente-a-erbitux-r-mas-folfox-en-el-cancer-colorrectal-localmente-avanzado-metastasico-con-estado-ras-braf-de-tipo-salvaje-y-mss-pmmr 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparing-efficacy-and-safety-of-enlituo-r-versus-erbitux-r-plus-folfox-in-locally-advanced-metastatic-colorectal-cancer-with-ras-braf-wild-type-and-mss-pmmr-status 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03829462/evaluacion-de-la-combinacion-de-regorafenib-e-irinotecan-frente-a-regorafenib-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03829462/assessing-a-regorafenib-irinotecan-combination-versus-regorafenib-alone-in-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07463599/seguridad-y-eficacia-de-tegavivint-en-pacientes-con-carcinoma-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07463599/safety-and-efficacy-of-tegavivint-in-patients-with-metastatic-colorectal-carcinoma 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/uso-de-la-metilacion-del-ctdna-para-monitorizar-el-tratamiento-del-cancer-colorrectal-metastasico-promet 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/using-ctdna-methylation-to-monitor-metastatic-colorectal-cancer-treatment-promet 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/ensayo-clinico-de-fase-ii-de-cadonilimab-en-combinacion-con-agentes-antiangiogenicos-en-el-cancer-colorrectal-metastasico-dmmr-msi-h 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/phase-ii-clinical-trial-of-cadonilimab-combined-with-anti-angiogenic-agents-in-metastatic-dmmr-msi-h-crc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06115733/estudio-de-fuquinitinib-en-combinacion-con-capecitabina-como-tratamiento-de-mantenimiento-de-primera-linea-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115733/study-of-fuquinitinib-combined-with-capecitabine-first-line-maintenance-in-the-treatment-of-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05848739/un-estudio-de-fase-1-2-de-st316-en-pacientes-con-tumores-solidos-avanzados-irresecables-y-metastasicos-seleccionados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05848739/a-phase-1-2-of-st316-with-selected-advanced-unresectable-and-metastatic-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/un-estudio-para-evaluar-la-eficacia-y-la-seguridad-de-la-quimioterapia-estandar-y-el-bevacizumab-con-o-sin-inca33890-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284849/a-study-to-evaluate-the-efficacy-and-safety-of-standard-of-care-chemotherapy-and-bevacizumab-with-or-without-inca33890-in-the-first-line-treatment-of-metastatic-microsatellite-stable-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05171660/combinacion-con-sintilimab-y-xelox-bevacizumab-como-terapia-de-primera-linea-en-el-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combination-with-sintilimab-and-xelox-bevacizumab-as-1st-line-therapy-in-ras-mutant-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02732860/modelado-personalizado-de-xenoinjertos-derivados-del-paciente-ppdx-para-evaluar-la-respuesta-a-farmacos-en-un-huesped-compatible 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02732860/personalized-patient-derived-xenograft-ppdx-modeling-to-test-drug-response-in-matching-host 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07602504/base-de-datos-del-registro-clinico-chino-de-pacientes-con-cancer-de-higado-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07602504/china-metastatic-liver-cancer-clinical-registry-cohort-database 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06525428/terapia-sistemica-estandar-combinada-con-radioterapia-en-dosis-altas-bajas-mas-toripalimab-para-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06525428/standard-systemic-therapy-combined-with-high-low-dose-radiotherapy-plus-toripalimab-for-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06242067/tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06242067/second-line-treatment-of-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07474025/integracion-de-los-patrones-de-crecimiento-histologico-peritoneal-en-la-toma-de-decisiones-preoperatorias-para-las-metastasis-peritoneales-del-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474025/integrating-peritoneal-histological-growth-patterns-into-preoperative-decision-making-for-colorectal-peritoneal-metastses 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/bloqueo-dual-de-egfr-her2-combinado-con-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico-her2-positivo 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/dual-egfr-her2-blockade-combined-with-irinotecan-for-the-treatment-of-her2-positive-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/quimiorradioterapia-seguida-de-cirugia-radical-en-pacientes-con-cancer-colorrectal-con-palnm 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05815082/quimioterapia-adyuvante-guiada-por-ctdna-en-metastasis-hepaticas-del-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05815082/ctdna-guided-adjuvant-chemotherapy-in-liver-metastasis-of-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/un-estudio-de-abt-301-mas-tislelizumab-con-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-pmmr-no-msi-h 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07244705/a-study-of-abt-301-plus-tislelizumab-with-bevacizumab-in-pmmr-non-msi-h-locally-advanced-or-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/seguridad-y-eficacia-de-fruquintinib-mas-chidamide-y-sintilimab-en-el-tratamiento-de-tercera-linea-o-posterior-del-cancer-colorrectal-metastasico-mss-pmmr 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685276/safety-and-efficacy-of-fruquintinib-plus-chidamide-and-sintilimab-in-the-third-and-later-line-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06493760/un-estudio-de-fase-ii-de-ssgj-707-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06493760/a-phase-2-study-of-ssgj-707-in-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/un-estudio-de-nx-1607-en-adultos-con-tumores-malignos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05107674/a-study-of-nx-1607-in-adults-with-advanced-malignancies 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-en-combinacion-con-fianlimab-para-el-cancer-colorrectal-no-metastasico-que-puede-ser-extirpado-quirurgicamente 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-with-fianlimab-for-resectable-non-metastatic-colon-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevencion-de-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-mediante-la-comparacion-de-huaier-con-la-monoterapia-con-capecitabina 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevention-of-recurrence-and-metastasis-of-colorectal-cancer-by-comparing-huaier-with-capecitabine-monotherapy 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06555003/quimioterapia-con-debiri-mas-otros-farmacos-frente-a-quimioterapia-sola-en-metastasis-hepaticas-del-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555003/debiri-plus-chemotherapy-vs-chemotherapy-alone-in-colorectal-cancer-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06283134/un-estudio-clinico-de-biottt001-en-combinacion-con-toripalimab-y-regorafenib-en-pacientes-con-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06283134/a-clinical-study-of-biottt001-in-combination-with-toripalimab-and-regorafenib-in-patients-with-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07221357/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-pumitamig-en-combinacion-con-quimioterapia-frente-a-bevacizumab-en-combinacion-con-quimioterapia-en-participantes-con-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07221357/a-study-to-evaluate-the-safety-and-efficacy-of-pumitamig-in-combination-with-chemotherapy-versus-bevacizumab-in-combination-with-chemotherapy-in-participants-with-previously-untreated-unresectable-or 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/estudio-abierto-con-bbo-10203-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/open-label-study-of-bbo-10203-in-subjects-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/terapia-celular-t-personalizada-ineo-vac-t01-en-cancer-colorrectal-avanzado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07504523/personalized-t-cell-therapy-ineo-vac-t01-in-advanced-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/mejora-de-la-supervivencia-en-metastasis-hepaticas-de-cancer-colorrectal-mediante-la-inmunostimulacion-inducida-por-ablacion-por-radiofrecuencia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/improving-survival-of-colorectal-liver-metastases-by-rfa-mediated-immunostimulation 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185245/trasplante-hepatico-para-metastasis-hepaticas-de-cancer-colorrectal-no-susceptibles-de-reseccion 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185245/liver-transplantation-for-non-resectable-colorectal-liver-metastasis 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05931445/estudio-de-resultados-informados-por-el-paciente-mediante-un-sistema-de-monitorizacion-electronica-para-cancer-solido-avanzado-o-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/patient-reported-outcomes-study-using-electronic-monitoring-system-for-advanced-or-metastatic-solid-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/aplicacion-de-la-terapia-con-insulina-en-dosis-altas-para-mejorar-la-funcion-y-regeneracion-hepatica 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06126419/application-of-high-dose-insulin-therapy-to-improve-liver-function-and-regeneration 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06200831/reseccion-simultanea-frente-a-reseccion-escalonada-del-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06200831/simultaneous-vs-staged-resection-of-colorectal-cancer-with-synchronous-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/el-estudio-gold-g8-en-pacientes-de-edad-avanzada 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/the-gold-study-g8-in-older-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549412/un-estudio-de-precemtabart-tocentecan-con-o-sin-bevacizumab-en-comparacion-con-trifluridina-tipiracil-mas-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-previamente-tratado-proceade 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-compared-to-trifluridine-tipiracil-plus-bevacizumab-in-participants-with-previously-treated-metastatic-colorectal-cancer-proceade-crc-03 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04940546/seguridad-del-tratamiento-neoadyuvante-con-sintilimab-xelox-bevacizumab-en-pacientes-con-metastasis-colorrectales-mcrlm-con-pmmr-mss 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/neoadjuvant-safety-of-sintilimab-xelox-bevacizumab-in-pmmr-mss-crlm-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06505551/estudio-de-fase-i-ii-de-celulas-t-con-receptores-de-celulas-t-autologas-scg142-en-pacientes-con-carcinoma-positivo-para-hpv16-52 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06505551/phase-1-2-study-of-autologous-scg142-tcr-t-cells-in-patients-with-hpv16-52-positive-carcinoma 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparacion-de-la-pet-rm-con-68ga-ga-ctr-fapi-y-18f-fdg-para-la-estadificacion-de-los-ganglios-linfaticos-en-el-cancer-de-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07552207/comparison-of-68ga-ga-ctr-fapi-and-18f-fdg-pet-mri-for-lymph-node-staging-in-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/evaluacion-de-ivonescimab-en-combinacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-sin-metastasis-hepaticas 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359456/testing-ivonescimab-in-combination-with-chemotherapy-in-patients-with-metastatic-colorectal-cancers-without-liver-metastases 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06185556/ensayo-coldfire-iii-eficacia-de-la-electroforesis-irreversible-y-la-radioterapia-estereotactica-corporal-en-metastasis-hepaticas-de-cancer-colorrectal-perivasculares-y-peribiliares 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06185556/coldfire-iii-trial-efficacy-of-irreversible-electroporation-and-stereotactic-body-radiotherapy-for-perivascular-and-peribiliary-colorectal-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/un-estudio-de-tucatinib-en-combinacion-con-trastuzumab-y-mfolfox6-frente-al-tratamiento-estandar-en-el-cancer-colorrectal-metastasico-her2-en-primera-linea 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05253651/a-study-of-tucatinib-with-trastuzumab-and-mfolfox6-versus-standard-of-care-treatment-in-first-line-her2-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-frente-a-bevacizumab-mas-quimioterapia-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras-fru-ras 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-versus-bevacizumab-plus-chemotherapy-in-second-line-ras-mutant-metastatic-colorectal-cancer-fru-ras 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-mas-cetuximab-en-un-nuevo-ciclo-de-tratamiento-versus-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-molecularmente-seleccionado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-plus-cetuximab-rechallenge-versus-trifluridine-tipiracil-plus-bevacizumab-in-molecularly-selected-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381309/virus-oncolitico-h101-radioterapia-estereotactica-ablativa-sbrt-quimioterapia-terapia-dirigida-inmunoterapia-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381309/oncolytic-virus-h101-sbrt-chemotherapy-targeted-therapy-immunotherapy-for-unresectable-crlm 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06764680/quimioterapia-oral-terapia-dirigida-e-inmunoterapia-con-o-sin-radioterapia-como-terapia-de-tercera-linea-o-posterior-para-el-cancer-colorrectal-avanzado-mss-pmmr 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06764680/oral-chemotherapy-targeted-therapy-and-immunotherapy-with-without-radiotherapy-as-3rd-or-later-line-therapy-for-advanced-mss-pmmr-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/ensayo-internacional-sobre-la-prevencion-de-metastasis-del-cancer-colorrectal-2 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03919461/colorectal-metastasis-prevention-international-trial-2 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195670/estudio-clinico-de-radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-sintilimab-frente-a-bevacizumab-mas-capecitabina-como-tratamiento-de-primera-linea-en-pacientes-con-mcrc-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195670/clinical-study-of-short-course-radiotherapy-followed-by-fruquintinib-plus-sintilimab-vs-bevacizumab-plus-capecitabine-as-first-line-treatment-in-advanced-mcrc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05489211/estudio-de-dato-dxd-como-monoterapia-y-en-combinacion-con-agentes-antineoplasicos-en-pacientes-con-tumores-solidos-avanzados-tropion-pantumor03 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05489211/study-of-dato-dxd-as-monotherapy-and-in-combination-with-anti-cancer-agents-in-patients-with-advanced-solid-tumours-tropion-pantumor03 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06199232/tratamiento-dirigido-mas-tislelizumab-y-haic-para-el-cancer-colorrectal-metastasico-crclm-en-estadio-avanzado-que-no-ha-respondido-al-tratamiento-sistemico-estandar 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06199232/targeted-treatment-plus-tislelizumab-and-haic-for-advanced-crclm-failed-from-standard-systemic-treatment 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/distribucion-de-los-ganglios-linfaticos-metastasicos-en-el-mesenterio-ileal-en-el-cancer-de-ciego-y-del-colon-ascendente-proximal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/metastatic-lymph-node-distribution-in-the-ileum-mesentery-of-cecal-and-proximal-ascending-colon-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03488953/trasplante-de-higado-con-donante-vivo-y-hepatectomia-en-dos-etapas-para-pacientes-con-metastasis-hepaticas-irresecables-aisladas-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03488953/living-donor-liver-transplantation-with-two-stage-hepatectomy-for-patients-with-isolated-irresectable-colorectal-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/validacion-prospectiva-de-un-modelo-de-inteligencia-artificial-para-predecir-la-metastasis-hepatica-en-el-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07392567/prospective-validation-of-an-ai-model-for-predicting-liver-metastasis-in-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05797077/terapia-de-mantenimiento-postoperatoria-para-metastasis-hepaticas-resecables-del-cancer-colorrectal-guiada-por-ctdna 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05797077/postoperation-maintenance-therapy-for-resectable-liver-metastases-of-colorectal-cancer-guided-by-ctdna 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06528353/deteccion-mediante-biomarcadores-sanguineos-en-el-cribado-de-cpc-impulsado-por-el-vph 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06528353/blood-biomarkers-based-screening-for-hpv-driven-opc 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06341309/estudio-exploratorio-de-liposomas-de-irinotecan-en-la-terapia-de-mantenimiento-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06341309/exploratory-study-of-irinotecan-liposomes-in-maintenance-therapy-of-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-en-combinacion-con-quimioterapia-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-ras 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-in-combination-with-chemotherapy-and-bevacizumab-in-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05970302/xelox-bevacizumab-tislelizumab-para-el-tratamiento-de-primera-linea-del-mcrc-con-mss-pmmr-y-mutacion-en-ras 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05970302/xelox-bev-tislelizumab-for-first-line-treatment-of-mss-pmmr-ras-mutated-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/oxaliplatino-sistemico-o-quimioterapia-intraarterial-combinada-con-lv5fu2-irinotecan-y-una-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-restringido-al-higado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/systemic-oxaliplatin-or-intra-arterial-chemotherapy-combined-with-lv5fu2-irinotecan-and-an-target-therapy-in-first-line-treatment-of-metastatic-colorectal-cancer-restricted-to-the-liver 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/prediccion-basada-en-inteligencia-artificial-de-la-metastasis-hepatica-en-el-cancer-colorrectal-un-estudio-retrospectivo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/un-estudio-multicentrico-de-fase-1b-2-con-adagrasib-cetuximab-y-cemiplimab-para-el-cancer-colorrectal-metastasico-que-presenta-mutaciones-kras-g12c 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/a-multicenter-phase-1b-2-study-of-adagrasib-cetuximab-and-cemiplimab-for-metastatic-colorectal-cancer-harboring-kras-g12c-mutations 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-con-metastasis-hepaticas 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-combined-with-pd-1-in-liver-metastasis-colorectal-cancer-patients 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03587480/reseccion-mesorrectal-total-rmt-con-diseccion-de-los-ganglios-linfaticos-laterales-frente-a-rmt-tras-quimiorradioterapia-neoadyuvante 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03587480/total-mesorectal-excision-tme-with-lateral-lymph-node-dissection-versus-tme-after-neoadjuvant-chemo-radiotherapy 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-celulas-nk-alogenicas-con-dosis-bajas-de-il-15-pembrolizumab-en-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-allogeneic-nk-cells-with-low-dose-il-15-pembrolizumab-in-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/estudio-clinico-de-fruquintinib-en-combinacion-con-raltitrexed-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/clinical-study-of-fruquintinib-combined-with-raltitrexed-in-the-treatment-of-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluacion-de-rbs2418-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-y-en-progresion 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824064/evaluation-of-rbs2418-in-patients-with-advanced-metastatic-and-progressive-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT01505400/ensayo-sobre-la-aplicacion-integrada-de-la-elaboracion-de-perfiles-moleculares-en-canceres-avanzados 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT01505400/integrated-molecular-profiling-in-advanced-cancers-trial 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06374173/un-estudio-de-fase-i-para-evaluar-tgi-6-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/a-phase-1-study-to-evaluate-tgi-6-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/rendimiento-de-la-tomografia-computarizada-espectral-en-pacientes-con-cancer-colorrectal-metastasico-un-estudio-multicentrico-prospectivo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06024837/performance-of-spectral-ct-scan-in-patients-with-metastatic-colorectal-cancer-a-prospective-multicentre-study 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06530303/terapia-con-linfocitos-infiltrantes-tumorales-mediante-inmunoterapia-para-el-cancer-de-colon-y-recto 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/biological-tumor-infiltrating-lymphocytes-therapy-with-immunotherapy-for-colon-and-rectum-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/perfusion-pulmonar-para-el-control-de-la-enfermedad-residual-minima-en-pacientes-con-sarcoma-o-metastasis-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446387/un-estudio-clinico-de-iparomlimab-y-tuvonralimab-en-combinacion-con-bevacizumab-y-un-regimen-de-capox-mcapiri-alternado-cada-tres-semanas-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446387/a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-bevacizumab-and-alternating-triweekly-capox-mcapiri-regimen-as-first-line-treatment-for-unresectable-advanced-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04616495/trasplante-hepatico-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04616495/liver-transplantation-in-patients-with-unresectable-colorectal-liver-metastases 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-y-bevacizumab-con-o-sin-pelareorep-para-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-ras-y-estable-en-microsatelites 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446322/folfiri-and-bevacizumab-with-or-without-pelareorep-for-second-line-treatment-of-metastatic-ras-mutated-microsatellite-stable-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07448662/estrategias-de-tratamiento-local-para-las-metastasis-cerebrales-del-cancer-colorrectal 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07448662/local-treatment-strategies-for-brain-metastases-of-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/panitumumab-administrado-de-forma-intermitente-o-continua-en-combinacion-con-folfiri-para-el-cancer-colorrectal-metastasico-de-lado-izquierdo-con-mutaciones-ras-b-raf-de-tipo-salvaje 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06509126/intermittent-or-continuous-panitumumab-plus-folfiri-for-left-sided-ras-b-raf-wild-type-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05771181/vitamina-e-en-combinacion-con-fruquintinib-y-tislelizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-microsatelites-estables 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05771181/vitamin-e-combined-with-fruquintinib-and-tislelizumab-in-microsatellite-stabilized-metastatic-colorectal-cancer-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-y-radioembolizacion-con-microsferas-de-166ho-en-el-cancer-colorrectal-metastasico-refractario 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-and-radioembolization-with-166ho-microspheres-in-refractory-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/un-estudio-sobre-la-quimioterapia-paliativa-en-segunda-linea-y-posteriores-en-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/a-study-of-second-and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05843188/estudio-de-hidroxicloroquina-con-folfiri-y-bevacizumab-en-cancer-colorrectal-metastasico-con-alto-nivel-de-dtp 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05843188/study-of-hydroxychloroquine-with-folfiri-and-bevacizumab-in-dtp-high-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05283330/seguridad-y-tolerabilidad-de-212pb-dotam-grpr1-en-sujetos-adultos-con-tumores-recurrentes-o-metastasicos-que-expresan-grpr 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05283330/safety-and-tolerability-of-212pb-dotam-grpr1-in-adult-subjects-with-recurrent-or-metastatic-grpr-expressing-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04868877/estudio-de-fase-i-ii-que-evalua-mcla-129-un-anticuerpo-humano-bispecifico-anti-egfr-y-anti-c-met-en-pacientes-con-cancer-de-pulmon-no-microcitico-cpnm-avanzado-y-otros-tumores-solidos-tanto-en 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04868877/phase-1-2-study-evaluating-mcla-129-a-human-anti-egfr-anti-c-met-bispecific-antibody-in-advanced-nsclc-and-other-solid-tumors-alone-and-in-combination 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/estudio-de-jdq443-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12c 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/study-of-jdq443-in-patients-with-advanced-solid-tumors-harboring-the-kras-g12c-mutation 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06580574/inhibidores-de-los-puntos-de-control-inmunitario-para-la-preservacion-de-organos-en-canceres-gastricos-o-de-colon-no-metastasicos-con-dmmr-msi-h 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06580574/immune-checkpoint-inhibitors-for-organ-preservation-in-non-metastatic-dmmr-msi-h-gastric-or-colon-cancers 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-administrado-por-via-hai-mas-irinotecan-intravenoso-con-o-sin-bevacizumab-frente-a-folfoxiri-sistemico-con-o-sin-bevacizumab-en-pacientes-con-metastasis-hepaticas-colorrectales-crlm 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05727163/folfox-via-hai-plus-intravenous-irinotecan-with-or-without-bevacizumab-versus-systemic-folfoxiri-with-or-without-bevacizumab-in-initially-unresectable-ras-mutated-crlm-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-y-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04245865/tocotrienol-and-bevacizumab-in-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06949982/eficacia-y-seguridad-de-la-hidroxicloroquina-en-combinacion-con-metotrexato-capecitabina-y-bevacizumab-frente-a-regorafenib-en-participantes-con-cancer-colorrectal-metastasico-refractario-con 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949982/efficacy-and-safety-of-hydroxychloroquine-combined-with-methotrexate-capecitabine-and-bevacizumab-vs-regorafenib-in-participants-with-refractory-metastatic-colorectal-cancer-with-mutations-in-ras 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/supervivientes-unidos-a-traves-de-ejercicios-guiados-a-distancia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/survivors-uniting-for-remote-guided-exercise 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06558773/inhibidor-de-la-sintetasa-gsl-en-combinacion-con-un-inhibidor-del-punto-de-control-inmunitario-y-o-regorafenib-en-pacientes-con-cancer-colorrectal-pmmr-mss-previamente-tratados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06558773/gsl-synthetase-inhibitor-plus-immune-checkpoint-inhibitor-and-or-regorafenib-in-previously-treated-pmmr-mss-crc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04017650/encorafenib-cetuximab-y-nivolumab-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-con-microsatelites-estables-y-mutacion-brafv600e 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04017650/encorafenib-cetuximab-and-nivolumab-in-treating-patients-with-microsatellite-stable-brafv600e-mutated-unresectable-or-metastatic-colorectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07488676/un-estudio-de-asp546c-en-adultos-con-cancer-gastroesofagico-cancer-de-pancreas-u-otros-tumores-solidos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07488676/a-study-of-asp546c-in-adults-with-gastroesophageal-cancer-pancreatic-cancer-or-other-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06523582/bases-geneticas-de-los-tumores-neuroendocrinos-en-pacientes-mexicanos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06523582/genetic-bases-of-neuroendocrine-neoplasms-in-mexican-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04802876/eficacia-de-tislelizumab-y-spartalizumab-en-diversos-tipos-de-cancer-en-pacientes-con-tumores-que-expresan-altos-niveles-de-arnm-de-pd1 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04802876/efficacy-of-tislelizumab-and-spartalizumab-across-multiple-cancer-types-in-patients-with-pd1-high-mrna-expressing-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06952101/un-enfoque-terapeutico-multimodal-personalizado-integrado-y-adaptado-al-estadio-a-nivel-mundial-para-el-adenocarcinoma-rectal-basado-en-la-preservacion-de-organos-y-la-minima-invasion 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06952101/a-global-integrated-personalized-stage-related-multimodal-therapeutic-approach-for-rectal-adenocarcinoma-based-on-organ-sparing-and-mininvasivity 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05824975/un-estudio-para-evaluar-la-seguridad-y-la-actividad-terapeutica-de-gi-102-como-agente-unico-y-en-combinacion-con-farmacos-antineoplasicos-convencionales-pembrolizumab-o-trastuzumab-deruxtecan-t-dxd 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05824975/a-study-to-evaluate-the-safety-and-therapeutic-activity-of-gi-102-as-a-single-agent-and-in-combination-with-conventional-anti-cancer-drugs-pembrolizumab-or-trastuzumab-deruxtecan-t-dxd-in-patients 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06540027/el-efecto-de-la-cirugia-minimamente-invasiva-sobre-la-respuesta-inflamatoria-sistemica-en-el-cancer-de-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT06540027/the-effect-of-minimally-invasive-surgery-on-systemic-inflammatory-response-in-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05669430/un-estudio-de-la-monoterapia-con-gv20-0251-y-la-combinacion-de-gv20-0251-con-pembrolizumab-en-participantes-con-tumores-solidos-malignos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05669430/a-study-of-gv20-0251-monotherapy-and-gv20-0251-in-combination-with-pembrolizumab-in-participants-with-solid-tumor-malignancies 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02465060/terapia-dirigida-basada-en-pruebas-geneticas-para-el-tratamiento-de-pacientes-con-tumores-solidos-avanzados-refractarios-linfomas-o-mieloma-multiple-el-ensayo-de-cribado-match 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02465060/targeted-therapy-directed-by-genetic-testing-in-treating-patients-with-advanced-refractory-solid-tumors-lymphomas-or-multiple-myeloma-the-match-screening-trial 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03678883/9-ing-41-en-pacientes-con-canceres-avanzados 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03678883/9-ing-41-in-patients-with-advanced-cancers 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02293954/el-uso-del-anticuerpo-monoclonal-marcado-con-cobre-64-cu-64-anti-cea-m5a-en-la-tomografia-por-emision-de-positrones-pet-para-el-diagnostico-de-pacientes-con-cancer-cea-positivo 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02293954/copper-cu-64-anti-cea-monoclonal-antibody-m5a-pet-in-diagnosing-patients-with-cea-positive-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02628067/estudio-de-pembrolizumab-mk-3475-en-participantes-con-tumores-solidos-avanzados-mk-3475-158-keynote-158 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02628067/study-of-pembrolizumab-mk-3475-in-participants-with-advanced-solid-tumors-mk-3475-158-keynote-158 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04083599/ensayo-de-seguridad-gen1042-y-actividad-antitumoral-en-participantes-con-tumores-solidos-malignos 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04083599/gen1042-safety-trial-and-anti-tumor-activity-in-participants-with-malignant-solid-tumors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07349537/estudio-de-rmc-5127-en-pacientes-con-tumores-solidos-avanzados-con-mutacion-kras-g12v 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349537/study-of-rmc-5127-in-patients-with-advanced-kras-g12v-mutant-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218914/estudio-de-fase-i-para-investigar-las-terapias-con-celulas-t-receptoras-quimericas-tcrt-dirigidas-a-la-mutacion-kras-en-tumores-solidos-avanzados-irresecables-y-o-metastasicos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218914/phase-1-study-to-investigate-tcrts-kras-mutation-in-unresectable-advanced-and-or-metastatic-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02912559/quimioterapia-combinada-con-o-sin-atezolizumab-en-el-tratamiento-de-pacientes-con-cancer-de-colon-en-estadio-iii-y-deficiencia-en-la-reparacion-del-desajuste-de-bases-del-adn 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02912559/combination-chemotherapy-with-or-without-atezolizumab-in-treating-patients-with-stage-iii-colon-cancer-and-deficient-dna-mismatch-repair 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03228667/quilt-3-055-un-estudio-sobre-la-combinacion-de-inmunoterapias-en-pacientes-que-previamente-han-recibido-tratamiento-con-inhibidores-de-puntos-de-control-inmunitario 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT03228667/quilt-3-055-a-study-of-combination-immunotherapies-in-patients-who-have-previously-received-treatment-with-immune-checkpoint-inhibitors 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT05686226/inmunoterapia-con-celulas-t-modificadas-con-e7-para-el-tratamiento-de-los-canceres-asociados-al-virus-del-papiloma-humano-vph 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT05686226/e7-tcr-t-cell-immunotherapy-for-human-papillomavirus-hpv-associated-cancers 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06508307/un-estudio-clinico-de-fase-i-sobre-la-inyeccion-intratumoral-del-virus-oncolitico-vaccinia-gc001-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06508307/a-phase-i-clinical-study-of-intratumoral-injection-oncolytic-vaccinia-virus-gc001-in-patient-with-advanced-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/cancer-colorrectal-en-estadio-ii-iii-con-recurrencia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06314958/stage-ii-iii-colorectal-cancer-recurrence 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04779554/dosis-fija-versus-quimioterapia-intraoperatoria-basada-en-el-peso-para-el-tratamiento-de-la-enfermedad-peritoneal-carcinomatosa-con-citoreduccion-y-quimioterapia-intraoperatoria-hipertermia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04779554/flat-dose-vs-weight-based-ip-chemotherapy-for-crs-hipec 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06703632/evaluacion-de-la-eficacia-de-prevecol-como-metodo-de-segunda-linea-para-la-deteccion-precoz-del-cancer-colorrectal 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06703632/evaluation-of-prevecol-s-efficiency-as-a-second-line-method-for-the-early-colorectal-cancer-detection 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06444815/un-estudio-de-vet3-tgi-en-pacientes-con-tumores-solidos 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06444815/a-study-of-vet3-tgi-in-patients-with-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303547/concordancia-entre-el-diagnostico-por-imagen-y-el-diagnostico-patologico-de-depositos-tumorales-extranodales 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT03303547/concordance-of-imaging-and-pathology-diagnosis-of-extranodal-tumour-deposits 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001085/monitorizacion-del-ctdna-en-pacientes-con-chc-y-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001085/ctdna-monitoring-in-patients-with-hcc-and-mcrc 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06266832/eficacia-y-seguridad-de-la-radioterapia-de-corta-duracion-combinada-con-adebrelimab-y-la-terapia-neoadyuvante-capeox-para-la-preservacion-de-organos-en-pacientes-con-adenocarcinoma-rectal-ultra-bajo 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT06266832/the-efficacy-and-safety-of-short-course-radiation-combined-with-adebrelimab-and-capeox-neo-adjuvant-therapy-for-organ-retention-in-patients-with-mss-pmmr-ultra-low-rectal-adenocarcinoma 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT00217737/oxaliplatino-leucovorina-y-fluorouracilo-con-o-sin-bevacizumab-en-el-tratamiento-de-pacientes-que-han-sido-sometidos-a-cirugia-por-cancer-de-colon-en-estadio-ii 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT00217737/oxaliplatin-leucovorin-and-fluorouracil-with-or-without-bevacizumab-in-treating-patients-who-have-undergone-surgery-for-stage-ii-colon-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07417488/vacunacion-con-gucy2c-mediante-estrategia-prime-boost-para-adenocarcinoma-colorrectal-avanzado-y-adenocarcinoma-de-intestino-delgado 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07417488/gucy2c-prime-boost-vaccination-for-advanced-colorectal-and-small-bowel-adenocarcinomas 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07440290/estudio-determine-rama-de-tratamiento-07-dabrafenib-en-combinacion-con-trametinib-en-pacientes-adultos-pediatricos-y-adolescentes-jovenes-con-canceres-braf-v600-mutacion-positivos 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07440290/determine-trial-treatment-arm-07-dabrafenib-in-combination-with-trametinib-in-adult-paediatric-and-teenage-young-adult-patients-with-braf-v600-mutation-positive-cancers 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07140679/inmunoterapia-toripalimab-para-reducir-el-riesgo-de-recurrencia-tras-la-cirugia-en-pacientes-con-cancer-de-colon-estadio-iib-iic-o-iii-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07140679/immunotherapy-toripalimab-for-reducing-recurrence-risk-after-surgery-for-mismatch-repair-deficient-stage-iib-iic-or-iii-colon-cancer 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07223424/preferencias-del-paciente-con-respecto-a-la-administracion-subcutanea-frente-a-la-intravenosa-de-inmunoterapia 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07223424/patient-preference-for-subcutaneous-vs-intravenous-immune-therapy 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020221/un-estudio-de-fase-1-2-de-vs-7375-en-pacientes-con-tumores-solidos-con-mutacion-kras-g12d 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020221/a-phase-1-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-solid-tumors 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281768/quimioterapia-con-capecitabina-oxaliplatino-y-cemiplimab-con-o-sin-fianlimab-o-regn7075-en-el-cancer-colorrectal-localmente-avanzado 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07281768/capecitabine-oxaliplatin-chemotherapy-and-cemiplimab-with-or-without-fianlimab-or-regn7075-in-locally-advanced-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT07292298/estudio-de-fase-ii-ensayo-de-un-solo-brazo-sobre-braquiterapia-en-pacientes-con-cancer-de-recto-y-adenocarcinoma-residual-localizado-en-la-parte-inferior-tras-la-terapia-neoadyuvante-total-con-el 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT07292298/phase-2-single-arm-rectal-cancer-brachytherapy-for-patients-with-low-lying-residual-adenocarcinoma-after-total-neoadjuvant-therapy-to-improve-organ-preservation-rates 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04907643/realidad-virtual-para-el-manejo-del-dolor-en-pacientes-con-cancer-gastrointestinal-con-el-fin-de-mejorar-los-resultados-informados-por-los-pacientes 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT04907643/virtual-reality-for-gi-cancer-pain-to-improve-patient-reported-outcomes 2026-06-02 weekly 0.7 https://crcwarriors.org/ensayo/NCT02688712/estudio-exist-de-ly2157299-galunisertib-en-cancer-de-recto 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT02688712/exist-study-of-ly2157299-galunisertib-in-rectal-cancer 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04147494/estudios-experimentales-con-tomografias-por-emision-de-positrones-pet-realizadas-antes-de-la-cirugia-del-cancer-para-analizar-la-cantidad-de-trazador-pet-acumulado-en-los-tejidos-normales-y-cancerosos 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04147494/experimental-pet-imaging-scans-before-cancer-surgery-to-study-the-amount-of-pet-tracer-accumulated-in-normal-and-cancer-tissues 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04729322/trasplante-de-microbiota-fecal-y-reintroduccion-de-la-terapia-anti-pd-1-pembrolizumab-o-nivolumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-en-pacientes-que-no-responden-a-la-terapia 2026-06-02 weekly 0.6 https://crcwarriors.org/ensayo/NCT04729322/fecal-microbiota-transplant-and-re-introduction-of-anti-pd-1-therapy-pembrolizumab-or-nivolumab-for-the-treatment-of-metastatic-colorectal-cancer-in-anti-pd-1-non-responders 2026-06-02 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-05-29 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-05-29 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-05-29 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-05-29 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-05-20 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-05-20 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-04-14 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-04-14 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-05-23 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-05-23 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-04-15 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-04-15 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/ibrutinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ibrutinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngr-htnf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngr-htnf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/venetoclax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/venetoclax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/si-b001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gm-ct-01 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/gm-ct-01/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/napabucasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/napabucasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isunakinra 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isunakinra/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tu2218 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tu2218/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trisulfate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/trisulfate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/liverpearls-irinotecan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/liverpearls-irinotecan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dkn-01 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dkn-01/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/icrucumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/icrucumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/treatme 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/treatme/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/cnto-328 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cnto-328/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/es104 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/es104/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tc-510 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tc-510/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cu-tz-sara 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cu-tz-sara/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/somatostatin 2026-05-28 weekly 0.7 https://crcwarriors.org/medicamento/somatostatin/ensayos 2026-05-28 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-awwb 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-awwb/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xl888 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl888/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pep503 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pep503/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-102 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ga-102/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/kzr-261 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kzr-261/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986490 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bms-986490/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/metarresti 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/metarresti/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eo2040 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/eo2040/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tak-186 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tak-186/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mgd009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mgd009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/qs21 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/qs21/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-706 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amg-706/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gen1042 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gen1042/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bempegaldesleukin 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bempegaldesleukin/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-05212384 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-05212384/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/catumaxomab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/catumaxomab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mva-209 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/mva-209/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/bnt314 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt314/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pb101 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pb101/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/cp-751 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cp-751/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nktr-262 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/nktr-262/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/nktr-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nktr-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golimumab 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/golimumab/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/prasterone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prasterone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bnt327 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bnt327/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gi-102 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gi-102/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/tinodasertib 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tinodasertib/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/danvatirsen 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/danvatirsen/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/gen-011 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gen-011/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/menthol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/menthol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/eco-4601 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/eco-4601/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/jmt108 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/jmt108/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/esg401 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/esg401/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/glucagon 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/glucagon/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab-deruxtecan/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/tas102 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/tas102/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/devimistat 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/devimistat/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/ak117 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/ak117/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/wnt974 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/wnt974/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/pf-06946860 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/pf-06946860/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/kqb368 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/kqb368/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/lt-002 2026-04-23 weekly 0.7 https://crcwarriors.org/medicamento/lt-002/ensayos 2026-04-23 weekly 0.6 https://crcwarriors.org/medicamento/gdc-0994 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/gdc-0994/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/disp-10 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/disp-10/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/clsp-1025 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/clsp-1025/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/paricalcitol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/paricalcitol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/alt803 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/alt803/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/dexpantenol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexpantenol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midostauri 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/midostauri/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ramosetron 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ramosetron/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rph-030 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/rph-030/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2294/superacion-de-la-resistencia-inmune-condicional-en-el-cancer-colorrectal-mss-y-pmmr-un-modelo-de-secuenciacion-escalonada-para-la-inmunoterapia 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2294/overcoming-conditional-immune-resistance-in-mss-and-pmmr-colorectal-cancer-a-sequential-gating-framework-for-immunotherapy 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2293/el-receptor-de-vitamina-d-en-los-tumores-una-revision-de-los-mecanismos-biologicos-los-posibles-usos-terapeuticos-y-los-valores-pronosticos 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2293/vitamin-d-receptor-in-tumors-a-review-of-biological-mechanisms-therapeutic-potentials-and-prognostic-values 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2280/la-ferroptosis-en-el-cancer-colorrectal-mecanismos-moleculares-y-la-interaccion-reguladora-con-posibles-aplicaciones-terapeuticas-revision 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2280/ferroptosis-in-colorectal-cancer-molecular-mechanisms-and-regulatory-crosstalk-with-therapeutic-prospects-review 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2257/la-neferina-al-potenciar-la-formula-shenling-baizhu-tang-refuerza-la-terapia-anti-pd-1-en-las-metastasis-hepaticas-del-cancer-colorrectal-a-traves-de-la-reprogramacion-lipidica-mediada-por-cyp2e1-ppar 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2257/neferine-enhanced-shenling-baizhu-tang-potentiates-anti-pd-1-therapy-in-colorectal-cancer-liver-metastasis-via-cyp2e1-ppar-mediated-lipid-reprogramming 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluacion-del-ct-adn-y-el-estado-mutacional-en-la-biopsia-liquida-de-pacientes-con-cancer-colorrectal-metastasico 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2158/evaluation-of-ct-dna-and-mutational-status-in-liquid-biopsy-of-patients-with-metastatic-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/1996/los-conjugados-peptido-farmaco-que-contienen-la-carga-antimitotica-ahx-da1-logran-una-potente-actividad-antitumoral-en-modelos-in-vivo-de-canceres-con-amplificacion-de-her2-positivos-para-egfr-y-con 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/1996/peptide-drug-conjugates-bearing-an-antimitotic-ahx-da1-payload-achieve-potent-antitumor-activity-in-her2-amplified-and-egfr-positive-kras-mutant-cancers-in-vivo 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/1623/las-probioticos-ingenierizados-despojados-de-metionina-promueven-la-inmunoterapia-con-anticuerpos-anti-pd-l1-al-activar-el-camino-sting 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/1623/methionine-depleting-engineered-probiotics-promote-pd-l1-antibody-immunotherapy-by-activating-the-sting-pathway 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/1607/aplicar-reguladores-nanomimeticos-para-fototerapia-in-situ-y-regulacion-de-lactato-con-el-fin-de-amplificar-la-terapia-inmunitaria-cuproptosis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/1607/harnessing-biomimetic-nano-regulators-for-in-situ-photothermia-and-lactate-regulation-to-amplify-cuproptosis-immunotherapy 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2307/identificacion-de-nuevos-variantes-geneticos-de-riesgo-asociados-con-el-accidente-cerebrovascular-isquemico-de-inicio-temprano-en-taiwan 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2307/identification-of-novel-genetic-risk-variants-associated-with-early-onset-ischemic-stroke-in-taiwan 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2306/discriminacion-precisa-de-polimorfismos-de-un-solo-nucleotido-mediante-el-ensamblaje-de-sondas-de-bloqueo-mediadas-por-pna-y-la-amplificacion-por-circulo-rodante-utilizando-pna-modificado-quimicamente 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2306/precision-discrimination-of-single-nucleotide-polymorphisms-via-chemically-engineered-pna-mediated-padlock-probe-assembly-and-rolling-circle-amplification 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2305/avances-recientes-en-las-plataformas-de-biosensores-que-utilizan-la-caracterizacion-de-biomarcadores-exosomicos-para-el-diagnostico-del-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2305/recent-advances-in-biosensing-platforms-utilizing-exosomal-biomarker-profiling-for-cancer-diagnosis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2304/respuesta-inflamatoria-sistemica-tras-la-cirugia-abdominal-robotica-frente-a-la-laparoscopica-una-revision-sistematica-y-metaanalisis-con-analisis-de-subgrupos-de-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2304/systemic-inflammatory-response-after-robotic-versus-laparoscopic-abdominal-surgery-a-systematic-review-and-meta-analysis-with-colorectal-cancer-subgroup-analysis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2302/mas-alla-del-5-fluorouracilo-convencional-estrategias-recientes-de-quimica-medicinal-para-mejorar-su-eficacia-antitumoral 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2302/beyond-conventional-5-fluorouracil-recent-medicinal-chemistry-strategies-to-enhance-its-anticancer-efficacy 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2301/un-nuevo-inhibidor-no-competitivo-de-p97-vcp-induce-apoptosis-y-autofagia-para-suprimir-el-crecimiento-del-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2301/a-novel-non-competitive-p97-vcp-inhibitor-induces-apoptosis-and-autophagy-to-suppress-colorectal-cancer-growth 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2300/un-estudio-aleatorizado-que-compara-encorafenib-cetuximab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-cancer-colorrectal-con-mutacion-braf-v600e-cohorte-3-del-estudio-breakwater 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2300/a-randomised-study-of-encorafenib-cetuximab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-in-braf-v600e-mutant-colorectal-cancer-breakwater-cohort-3 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2299/la-produccion-a-escala-clinica-de-celulas-tcr-t-durante-10-dias-utilizando-il-2-7-15-y-tgf-promueve-tempranamente-fenotipos-de-memoria-y-similares-a-celulas-residentes-en-los-tejidos-y-una-robusta 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2299/clinical-scale-10-day-tcr-t-cell-manufacturing-using-il-2-7-15-and-tgf-promotes-early-memory-and-tissue-resident-like-phenotypes-and-robust-antitumor-activity-in-vitro 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2298/superacion-de-la-resistencia-adaptativa-al-bloqueo-de-krasg12d-en-el-cancer-de-pancreas-mediante-la-inhibicion-de-la-via-de-senalizacion 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2298/overcoming-adaptive-resistance-to-krasg12d-blockade-in-pancreatic-cancer-through-vertical-pathway-inhibition 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2287/estudio-computacional-de-los-complejos-supramoleculares-de-actinonina-cucurbiturilo-8-para-la-terapia-del-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2287/computational-study-of-actinonin-cucurbit-8-uril-supramolecular-complexes-for-colorectal-cancer-therapy 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2286/secuenciacion-rapida-de-proxima-generacion-in-situ-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2286/rapid-on-site-next-generation-sequencing-an-alternative-to-single-gene-and-send-out-testing-in-non-small-cell-lung-cancer-and-colorectal-cancer-in-a-community-pathology-laboratory-setting 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2281/la-senalizacion-de-cxcr3-favorece-el-reclutamiento-de-celulas-t-delta-one-y-la-eficacia-antitumoral-en-el-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2281/cxcr3-signaling-promotes-delta-one-t-cell-recruitment-and-antitumor-efficacy-in-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2278/analisis-integrativo-de-biomarcadores-circulantes-del-cancer-colorrectal-mediante-la-combinacion-de-espectroscopia-de-infrarrojo-medio-y-metabolomica-dirigida 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2278/integrative-analysis-of-circulating-biomarkers-of-colorectal-cancer-combining-mid-infrared-spectroscopy-and-targeted-metabolomics 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2277/accion-fotocitotoxica-de-un-colorante-cianinico-con-dos-cromoforos-formacion-del-radical-anion-superoxido 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2277/photocytotoxic-action-of-cyanine-dye-with-two-chromophores-formation-of-superoxide-anion-radical 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2275/descubrimiento-de-andamios-tetraciclicos-de-azaindol-indol-fusionados-con-pirimidina-como-nuevos-inhibidores-potentes-de-cdk7 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2275/discovery-of-azaindole-indole-fused-pyrimidine-tetracyclic-scaffolds-as-novel-potent-cdk7-inhibitors 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2274/dirigirse-a-la-proteina-bmx-en-el-cancer-mecanismos-moleculares-y-estrategias-terapeuticas-emergentes 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2274/targeting-the-bmx-in-cancer-molecular-mechanisms-and-emerging-therapeutic-strategies 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2273/descifrando-el-microbioma-avances-en-el-microambiente-intestinal-dirigidos-por-inteligencia-artificial-para-lograr-avances-en-la-terapia-oncologica-personalizada 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2273/decoding-the-microbiome-artificial-intelligence-targeted-gut-microenvironment-breakthroughs-in-personalized-cancer-therapy 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2272/metabolomica-asistida-por-analisis-transcriptomico-para-revelar-caracteristicas-metabolicas-y-biomarcadores-potenciales-del-cancer-colorrectal-de-aparicion-temprana 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2272/metabolomics-assisted-by-transcriptomics-analysis-to-reveal-metabolic-characteristics-and-potential-biomarkers-of-early-onset-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2271/parametros-de-la-fdg-pet-tc-para-diferenciar-entre-alta-y-baja-inestabilidad-de-microsatelites-en-el-cancer-colorrectal-una-revision-sistematica-y-metaanalisis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2271/fdg-pet-ct-parameters-for-distinguishing-high-and-low-microsatellite-instability-in-colorectal-cancer-a-systematic-review-and-meta-analysis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2270/estrategias-actuales-y-nuevos-enfoques-de-la-inmunoterapia-en-el-cancer-colorrectal-con-estabilidad-microsatelital-un-articulo-de-revision 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2270/current-strategies-and-emerging-paradigms-of-immunotherapy-in-microsatellite-stable-colorectal-cancer-a-review-article 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2269/eficacia-del-bloqueo-dual-kras-g12d-egfr-frente-a-combinaciones-triples-en-modelos-derivados-de-pacientes-de-cancer-colorrectal-con-mutacion-kras-g12d 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2269/efficacy-of-dual-kras-g12d-egfr-blockade-versus-triple-combinations-in-patient-derived-models-of-kras-g12d-mutant-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2268/las-mutaciones-de-kras-g12v-a146t-se-asocian-con-resistencia-a-la-quimiorradioterapia-neoadyuvante-ncrt-a-traves-de-una-mayor-reparacion-de-las-roturas-de-doble-cadena-del-adn-y-respaldan-un-marco-de 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2268/kras-g12v-a146t-mutations-are-associated-with-ncrt-resistance-via-enhanced-dna-double-strand-break-repair-and-support-a-deep-learning-prediction-framework-in-larc 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2265/un-estudio-exploratorio-in-vitro-de-la-citotoxicidad-y-el-perfil-de-citoquinas-de-las-celulas-asesinas-inducidas-por-citoquinas-cik-contra-las-celulas-de-cancer-colorrectal-crc-hct-15 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2265/an-exploratory-in-vitro-study-of-cytotoxicity-and-cytokine-profiling-of-cytokine-induced-killer-cik-cells-against-hct-15-colorectal-cancer-crc-cells 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2264/superando-las-barreras-inmunologicas-mediadas-por-pequenas-vesiculas-extracelulares-en-el-microambiente-tumoral-mediante-peptidos-pegilados-que-se-pueden-activar-estrategicamente 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2264/combating-small-extracellular-vesicle-mediated-immunological-barriers-in-the-tumor-microenvironment-via-strategically-activatable-pegylated-peptides 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2263/conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-diseno-molecular-avances-preclinicos-y-desafios-traslacionales 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2263/antibody-drug-conjugates-in-colorectal-cancer-molecular-design-preclinical-advances-and-translational-challenges 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2262/sintilimab-mas-fruquintinib-con-o-sin-radioterapia-como-tratamiento-de-tercera-linea-para-el-cancer-colorrectal-con-metastasis-hepaticas-protocolo-de-estudio-para-un-ensayo-aleatorizado-multicentrico 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2262/sintilimab-plus-fruquintinib-with-or-without-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases-study-protocol-for-a-randomized-controlled-multicenter-phase-ii-trial 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2261/quimiorradioterapia-adyuvante-frente-a-reseccion-total-del-meso-recto-complementaria-tras-reseccion-local-para-el-cancer-de-recto-en-estadio-temprano-tesar-un-ensayo-multicentrico-aleatorizado 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2261/adjuvant-chemoradiotherapy-versus-completion-total-mesorectal-excision-after-local-excision-for-early-rectal-cancer-tesar-a-multicentre-randomised-controlled-phase-3-non-inferiority-trial 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2256/efecto-de-la-terapia-antitumoral-previa-dirigida-contra-el-egfr-y-de-la-caracterizacion-inicial-del-ctdna-en-la-eficacia-de-pertuzumab-mas-trastuzumab-en-el-cancer-colorrectal-metastasico-con 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2256/effect-of-prior-anti-egfr-therapy-and-baseline-ctdna-profiling-on-the-efficacy-of-pertuzumab-plus-trastuzumab-in-her2-amplified-metastatic-colorectal-cancer-an-integrated-analysis-of-triumph-mypathway 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2255/la-deficiencia-de-plscr3-desencadena-la-activacion-del-cgas-sting-impulsada-por-el-adn-mitocondrial-para-potenciar-la-inmunidad-antitumoral-en-el-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2255/plscr3-deficiency-triggers-mtdna-driven-cgas-sting-activation-to-potentiate-antitumor-immunity-in-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2251/el-impacto-de-la-mutacion-de-apc-en-la-eficacia-de-la-terapia-anti-egfr-en-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-un-analisis-retrospectivo 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2251/the-impact-of-apc-mutation-on-the-efficacy-of-anti-egfr-therapy-in-metastatic-colorectal-cancer-with-ras-wild-type-a-retrospective-analysis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2250/caracterizacion-espectroscopica-raman-de-los-cambios-proteicos-inducidos-por-el-5-fluorouracilo-en-celulas-de-cancer-de-colon 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2250/raman-spectroscopic-characterization-of-protein-changes-induced-by-5-fluorouracil-in-colon-cancer-cells 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2246/evolucion-del-microambiente-inmunitario-a-lo-largo-de-la-via-de-la-neoplasia-serrada-y-su-relevancia-para-la-inmunoterapia 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2246/immune-microenvironment-evolution-across-the-serrated-neoplasia-pathway-and-its-relevance-to-immunotherapy 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2245/evaluacion-de-un-ensayo-de-pcr-digital-de-gotas-para-la-deteccion-de-inestabilidad-de-microsatelites-en-cancer-colorrectal-cancer-gastrico-y-cancer-endometrial 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2245/evaluation-of-droplet-digital-pcr-assay-for-the-detection-of-microsatellite-instability-in-colorectal-gastric-and-endometrial-cancers 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2244/comprender-las-promesas-y-los-desafios-de-la-terapia-independiente-del-tipo-de-tumor-podria-una-unica-opcion-terapeutica-ser-realmente-adecuada-para-todos-los-pacientes 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2244/understanding-the-promise-and-challenges-of-tumor-agnostic-therapy-could-one-size-really-fit-all 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-en-combinacion-con-3-metiladenina-para-el-tratamiento-del-cancer-de-pancreas-con-mutacion-kras-g12c-y-sus-mecanismos-subyacentes 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2243/sotorasib-combined-with-3-methyladenine-for-the-treatment-of-kras-g12c-mutant-pancreatic-cancer-and-its-underlying-mechanisms 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2235/respuesta-duradera-a-selpercatinib-en-un-cancer-colorrectal-metastasico-que-presenta-una-nueva-fusion-timm23b-ret-informe-de-un-caso 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2235/durable-response-to-selpercatinib-in-metastatic-colorectal-cancer-harboring-a-novel-timm23b-ret-fusion-a-case-report 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2234/respuesta-patologica-completa-tras-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-con-deficiencia-en-el-sistema-de-reparacion-de-errores-mismatch-repair-e-invasion-de-organos-adyacentes 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2234/complete-pathologic-response-after-neoadjuvant-immunotherapy-for-mismatch-repair-deficient-colon-cancer-with-invading-adjacent-organs 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2232/la-plataforma-de-oncologia-de-precision-funcional-de-organoides-de-cancer-colorrectal-con-mutacion-braf-v600e-predice-la-respuesta-al-tratamiento-y-revela-la-inmunogenicidad-mediada-por-rnf43 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2232/functional-precision-oncology-platform-of-braf-v600e-mutated-colorectal-cancer-organoids-predicts-therapy-response-and-reveals-rnf43-mediated-immunogenicity 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2231/analisis-de-costo-efectividad-del-encorafenib-en-cancer-colorrectal-metastasico-braf-v600e-no-tratado-en-china 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2231/cost-effectiveness-analysis-of-encorafenib-in-untreated-braf-v600e-mutant-metastatic-colorectal-cancer-in-china 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2226/preactivacion-con-citocinas-y-citotoxicidad-celular-dependiente-de-anticuerpos-adcc-una-estrategia-eficaz-para-potenciar-las-funciones-efectoras-de-las-celulas-nk-humanas-frente-a-modelos-tumorales 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2226/cytokine-preactivation-and-adcc-a-potent-strategy-for-enhancing-human-nk-cell-effector-functions-against-3d-tumor-models 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2225/estudio-multicentrico-de-fase-ii-que-evalua-el-regimen-folfoxiri-neoadyuvante-seguido-de-quimiorradioterapia-concurrente-en-pacientes-chinos-con-cancer-de-recto-de-alto-riesgo 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2225/multicenter-phase-ii-study-of-neoadjuvant-folfoxiri-followed-by-concurrent-chemoradiotherapy-in-chinese-patients-with-high-risk-rectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2224/alteracion-del-ritmo-circadiano-en-el-cancer-colorrectal-la-cronoterapia-como-una-prometedora-estrategia-de-medicina-de-precision 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2224/circadian-disruption-in-colorectal-cancer-promise-of-chronotherapy-as-precision-medicine 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2221/analisis-de-la-toxicidad-a-lo-largo-del-tiempo-de-la-terapia-de-mantenimiento-basada-en-anti-egfr-frente-a-la-estrategia-de-tratamiento-intermitente-en-el-cancer-colorrectal-metastasico-del-lado 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2221/toxicity-over-time-analysis-of-anti-egfr-based-maintenance-versus-stop-go-in-left-sided-ras-braf-wild-type-metastatic-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2220/la-nanomedicina-que-se-adhiere-a-los-macrofagos-y-coadministra-gemcitabina-e-inhibidor-de-kras-g12d-orquesta-una-quimioinmunoterapia-para-el-cancer-colorrectal-metastasico 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2220/macrophage-hitchhiking-nanomedicine-codelivering-gemcitabine-and-kras-g12d-inhibitor-orchestrates-chemo-immunotherapy-for-metastatic-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2212/metastasis-hepaticas-de-cancer-colorrectal-estrategias-de-imagen-para-el-diagnostico-la-planificacion-del-tratamiento-local-y-la-evaluacion-de-la-respuesta-al-tratamiento-sistemico 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2212/colorectal-liver-metastases-imaging-strategies-for-diagnosis-local-treatment-planning-and-systemic-treatment-response 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2207/estudio-mecanicista-de-la-regulacion-farmacodinamica-en-la-tumorigenesis-modificacion-epigenetica-de-enzimas-clave-mediante-componentes-activos-de-ginsenosidos 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2207/mechanistic-study-of-pharmacodynamic-regulation-in-tumorigenesis-epigenetic-targeting-of-key-enzymes-by-active-ginsenoside-components 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2205/comparacion-indirecta-ajustada-por-emparejamiento-de-sotorasib-mas-panitumumab-frente-a-trifluridina-tipiracilo-mas-bevacizumab-en-cancer-colorrectal-metastasico-quimiorrefractario 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2205/matching-adjusted-indirect-comparison-of-sotorasib-plus-panitumumab-versus-trifluridine-tipiracil-plus-bevacizumab-in-chemorefractory-metastatic-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2200/los-anticuerpos-bispecificos-dirigidos-al-tumor-inhiben-eficazmente-las-vias-oncogenicas-al-tiempo-que-minimizan-la-toxicidad 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2200/tumor-targeted-bispecific-antibodies-effectively-inhibit-oncogenic-pathways-while-minimizing-toxicity 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2198/un-modelo-de-deteccion-automatica-de-la-diseminacion-a-traves-de-los-espacios-aereos-en-secciones-patologicas-postoperatorias-basado-en-el-aprendizaje-profundo-en-el-cancer-de-pulmon-no-microcitico 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2198/an-automatic-detection-model-for-spread-through-air-spaces-in-postoperative-pathological-sections-based-on-deep-learning-in-nsclc 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2194/analisis-de-la-eficacia-y-los-riesgos-de-la-monoterapia-y-la-inmunoterapia-combinada-en-el-cancer-colorrectal-metastasico-con-dmmr-msi-h-un-metaanalisis-basado-en-ensayos-clinicos-aleatorizados-y 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2194/efficacy-and-risk-analysis-of-monotherapy-and-dual-immunotherapy-in-dmmr-msi-h-metastatic-colorectal-cancer-a-meta-analysis-based-on-randomized-controlled-trials 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2193/complete-remission-following-targeted-therapy-in-braf-v600e-mutant-pulmonary-lymphangitic-carcinomatosis-secondary-to-rectal-cancer-a-case-report 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2192/los-subtipos-de-mutacion-de-kras-permiten-una-mejor-estratificacion-pronostica-en-el-cancer-colorrectal-un-estudio-retrospectivo-de-cohortes 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2192/kras-mutation-subtypes-refine-prognostic-stratification-in-colorectal-cancer-a-retrospective-cohort-study 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2189/comentarios-sobre-el-articulo-titulado-el-potencial-diagnostico-de-los-compuestos-organicos-volatiles-en-la-orina-para-la-deteccion-de-neoplasias-colorrectales-en-el-sindrome-de-lynch-un-estudio 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2189/comments-on-the-diagnostic-potential-of-urinary-volatile-organic-compounds-for-colorectal-neoplasia-in-lynch-syndrome-a-prospective-longitudinal-study 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2186/diseno-sintesis-y-estudio-de-la-relacion-estructura-actividad-de-nuevos-compuestos-con-un-andamiaje-de-indolo-pirrol-dirigidos-a-nur77-en-celulas-tumorales-de-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2186/design-synthesis-and-structure-activity-relationship-study-of-novel-indole-pyrrole-scaffold-compounds-targeting-nur77-in-colorectal-tumor-cells 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2185/la-deteccion-frecuente-de-mutaciones-en-kras-g12c-y-pik3ca-q546k-en-tumores-map-pone-de-relieve-su-papel-en-la-reclasificacion-de-variantes-mutyh-de-significado-incierto 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2185/frequent-detection-of-kras-g12c-and-pik3ca-q546k-mutations-in-map-tumors-highlights-their-role-in-mutyh-variants-of-uncertain-significance-reclassification 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2183/las-mutaciones-de-kras-y-braf-modifican-los-resultados-de-la-quimioterapia-adyuvante-en-el-cancer-colorrectal-en-estadio-temprano 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2183/kras-and-braf-mutations-modify-adjuvant-chemotherapy-outcomes-in-early-stage-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2179/biomarcadores-plasmaticos-asociados-con-los-resultados-clinicos-del-regimen-folfiri-mas-ramucirumab-en-el-cancer-colorrectal-metastasico-con-ras-tipo-salvaje-el-ensayo-jaccro-cc-16ar 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2179/plasma-biomarkers-associated-with-clinical-outcomes-of-folfiri-plus-ramucirumab-in-ras-wild-type-metastatic-colorectal-cancer-the-jaccro-cc-16ar-trial 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2178/efectos-pronosticos-y-relacionados-con-el-tratamiento-sobre-la-supervivencia-de-la-inestabilidad-de-microsatelites-en-los-diferentes-estadios-de-la-enfermedad-en-el-cancer-de-colon-un-analisis-de-la 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2178/prognostic-and-treatment-associated-survival-effects-of-microsatellite-instability-across-disease-stages-in-colon-cancer-an-ncdb-analysis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2176/establecimiento-de-una-radioinmunodiagnosis-predirigida-basada-en-68-ga-dota 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2176/establishment-of-68-ga-dota-based-pretargeted-radioimmunodiagnosis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2175/descifrando-el-paradigma-multifuncional-y-traslacional-de-los-sistemas-nanoparticulados-contra-el-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2175/unraveling-the-multifunctional-and-translational-paradigm-of-nanoparticulate-systems-against-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2173/un-ensayo-clinico-nacional-multicentrico-aleatorizado-controlado-de-grupos-paralelos-de-fase-iii-que-compara-el-tratamiento-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-al-tratamiento 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2173/a-national-multicentre-randomised-controlled-parallel-arms-phase-iii-clinical-trial-of-neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-in-patients 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2171/adn-tumoral-circulante-y-biomarcadores-de-precision-en-el-cancer-colorrectal-implicaciones-para-el-diagnostico-seguimiento-y-manejo-de-la-enfermedad-avanzada 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2171/circulating-tumor-dna-and-precision-biomarkers-in-colorectal-cancer-implications-for-diagnosis-monitoring-and-management-of-advanced-disease 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2170/la-via-de-senalizacion-mapk-erk-en-el-cancer-colorrectal-avances-recientes-y-nuevos-conocimientos 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2170/the-mapk-erk-signaling-pathway-in-colorectal-cancer-recent-advances-and-emerging-insights 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2162/mutaciones-oncogenicas-frecuentes-en-el-cancer-colorrectal-factores-clave-en-la-carcinogenesis-y-posibles-dianas-terapeuticas 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2162/common-oncogenic-mutations-in-colorectal-cancer-drivers-of-carcinogenesis-and-potential-therapeutic-targets 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2160/oncologia-de-precision-facilitada-por-la-cirugia-en-un-sarcoma-de-la-arteria-pulmonar-msi-h-con-sindrome-de-lynch-un-caso-clinico 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2160/surgery-enabled-precision-oncology-in-an-msi-high-pulmonary-artery-sarcoma-with-lynch-syndrome-a-case-report 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2156/caracterizacion-preclinica-y-resultados-de-la-fase-1-de-tqb2102-un-conjugado-anticuerpo-farmaco-biparatopico-her2-de-primera-generacion-en-pacientes-con-tumores-solidos-avanzados 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2156/preclinical-characterization-and-phase-1-results-of-tqb2102-a-first-in-class-her2-biparatopic-antibody-drug-conjugate-in-patients-with-advanced-solid-tumors 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2155/eficacia-de-la-dieta-mediterranea-para-la-prevencion-primaria-de-enfermedades-oncologicas-una-revision-sistematica-y-metaanalisis-que-se-incluye-en-las-guias-nacionales-italianas-la-dieta-mediterranea 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2155/efficacy-of-mediterranean-diet-for-the-primary-prevention-of-oncological-diseases-a-systematic-review-and-meta-analysis-featured-in-the-italian-national-guidelines-la-dieta-mediterranea 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2154/prx5-como-un-factor-clave-en-la-regulacion-de-la-capacidad-de-auto-renovacion-y-la-tumorigenicidad-de-las-celulas-madre-del-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2154/prx5-as-a-critical-driver-of-colorectal-cancer-stemness-and-tumorigenicity 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2153/caracteristicas-y-resultados-de-pacientes-con-neoplasias-previas-al-cancer-colorrectal-un-analisis-de-concordancia-por-puntuacion-de-propension 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2153/characteristics-and-outcomes-of-patients-with-malignancies-prior-to-colorectal-cancer-a-propensity-score-matched-analysis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2152/endometriosis-y-cancer-de-ovario-evidencia-epidemiologica-conocimientos-moleculares-y-toma-de-decisiones-clinicas 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2152/endometriosis-and-ovarian-cancer-epidemiological-evidence-molecular-insights-and-clinical-decision-making 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2149/ensayo-de-adn-tumoral-circulante-libre-de-tejido-y-resultados-en-pacientes-en-un-ensayo-de-fase-iii-de-quimioterapia-adyuvante-basada-en-folfox-alliance-n0147 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2149/tissue-free-circulating-tumor-dna-assay-and-patient-outcome-in-a-phase-iii-trial-of-folfox-based-adjuvant-chemotherapy-alliance-n0147 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2148/un-modelo-basado-en-organoides-ortotopicos-para-estudiar-la-disfuncion-temprana-de-celulas-t-cd8-y-la-respuesta-a-la-inmunoterapia-en-el-cancer-colorrectal 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2148/an-orthotopic-organoid-based-model-to-study-early-cd8-t-cell-dysfunction-and-immunotherapy-response-in-colorectal-cancer 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2144/terapia-con-celulas-v1t-car-alogenicas-dirigidas-contra-b7-h3-en-tumores-solidos-avanzados-un-estudio-de-fase-i 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2144/allogeneic-b7-h3-targeted-car-v1t-cell-therapy-in-advanced-solid-tumors-a-phase-i-study 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2133/troxerutina-como-flavonoide-bioactivo-perspectivas-sobre-sus-mecanismos-anticancerigenos-y-aplicaciones-terapeuticas 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2133/troxerutin-as-a-bioactive-flavonoid-insights-into-its-anticancer-mechanisms-and-therapeutic-applications 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2132/optimizacion-estructural-de-los-inhibidores-de-la-tirosil-adn-fosfodiesterasa-1-basados-en-benzofenantridinona-y-benzofenantridina-y-su-actividad-de-potenciacion-de-la-radioterapia 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2132/structural-optimization-of-benzophenanthridinone-and-benzophenanthridine-tyrosyl-dna-phosphodiesterase-1-inhibitors-and-their-radiosensitizing-activity 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2127/seguridad-y-eficacia-de-folfiri-3-irinotecan-en-dosis-divididas-para-el-cancer-colorrectal-irresecable-un-analisis-estratificado-basado-en-los-polimorfismos-del-gen-ugt1a1 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2127/safety-and-efficacy-of-folfiri-3-split-dose-irinotecan-for-unresectable-colorectal-cancer-a-stratified-analysis-based-on-ugt1a1-gene-polymorphisms 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2126/evaluaciones-pragmaticas-de-tecnologias-sanitarias-de-biosimilares-un-estudio-piloto-sobre-el-uso-de-bevacizumab-en-el-cancer-colorrectal-para-nice 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2126/pragmatic-health-technology-appraisals-of-biosimilars-a-pilot-case-study-of-bevacizumab-in-colorectal-cancer-for-nice 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2122/informe-de-caso-adenocarcinomas-colorrectales-sincronicos-con-estado-de-reparacion-del-desajuste-discordante-un-caso-de-sindrome-similar-a-lynch-y-asociacion-con-la-via-serrada 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2122/case-report-synchronous-colorectal-adenocarcinomas-with-discordant-mismatch-repair-status-a-case-of-lynch-like-syndrome-and-serrated-pathway-association 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2120/el-acido-urico-soluble-induce-el-agotamiento-de-los-linfocitos-t-cd8-al-provocar-una-hiperactivacion-mediada-por-ksr1-de-la-via-mapk 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2120/soluble-uric-acid-drives-cd8-t-cell-exhaustion-by-inducing-ksr1-mediated-mapk-hyperactivation 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2114/ensayos-de-microscopia-de-inmunofluorescencia-multiple-para-la-evaluacion-farmacodinamica-de-la-activacion-de-la-tirosina-quinasa-met-en-la-membrana-plasmatica-y-el-nucleo 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2114/multiplex-immunofluorescence-microscopy-assays-for-pharmacodynamic-assessment-of-met-tyrosine-kinase-activation-in-the-plasma-membrane-and-nucleus 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2113/panorama-genomico-completo-de-erbb2-en-tumores-gastrointestinales-chinos-panoramas-centrados-en-mutaciones-y-oportunidades-de-tratamiento-de-precision 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2113/comprehensive-genomic-landscape-of-erbb2-in-chinese-gi-tumors-mutation-centered-landscapes-and-precision-treatment-opportunities 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2111/optimizacion-de-la-terapia-con-pembrolizumab-para-el-cancer-colorrectal-metastasico-de-novo-msi-h-dmmr-mediante-el-uso-de-ecuaciones-integro-diferenciales-basadas-en-datos 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2111/optimisation-of-pembrolizumab-therapy-for-de-novo-metastatic-msi-h-dmmr-colorectal-cancer-using-data-driven-delay-integro-differential-equations 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2110/las-mutaciones-que-son-el-objetivo-de-la-inmunoterapia-nous-209-aparecen-en-las-primeras-etapas-de-las-lesiones-precancerosas-de-los-portadores-del-sindrome-de-lynch-que-presentan-inestabilidad-de 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2110/mutations-targeted-by-nous-209-immunotherapy-occur-early-in-lynch-syndrome-carriers-precancer-lesions-with-microsatellite-instability 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2102/la-transcripcion-y-el-empalme-no-canonicos-modelan-el-inmunopeptidoma-del-cancer-colorrectal-en-tumores-msi-y-mss 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2102/non-canonical-transcription-and-splicing-shape-the-colorectal-cancer-immunopeptidome-in-msi-and-mss-tumors 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2099/alteracion-de-la-interaccion-entre-el-lipopolisacarido-bacteriano-y-las-celulas-inmunitarias-en-el-cancer-colorrectal-en-comparacion-con-el-tejido-intestinal-adyacente 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2099/altered-crosstalk-of-bacterial-lipopolysaccharide-with-immune-cells-in-colorectal-cancer-compared-to-paired-adjacent-intestinal-tissue 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2096/descifrando-la-heterogeneidad-de-las-celulas-del-cancer-colorrectal-identificacion-de-biomarcadores-y-subpoblaciones-celulares-impulsoras-de-la-enfermedad-mediante-scissor-y-cibersortx-en-el-analisis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2096/unveiling-colorectal-cancer-cell-heterogeneity-identification-of-biomarkers-and-disease-driving-cell-subpopulations-through-scissor-and-cibersortx-on-integrated-transcriptomic-profiling 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2095/el-aprendizaje-profundo-consciente-de-firmas-revela-distintos-programas-de-genes-conductores-y-procesos-mutacionales-en-glioblastoma-y-adenocarcinoma-de-colon 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2095/signature-aware-deep-learning-reveals-distinct-driver-gene-programs-and-mutational-processes-in-glioblastoma-and-colon-adenocarcinoma 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2094/puntuacion-revisada-de-la-carga-tumoral-para-la-estratificacion-pronostica-en-pacientes-con-cancer-colorrectal-metastasico-que-reciben-inmunoterapia-un-estudio-retrospectivo 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2094/revised-tumor-burden-score-for-prognostic-stratification-in-metastatic-colorectal-cancer-patients-receiving-immunotherapy-a-retrospective-study 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2087/resistencia-adquirida-a-los-inhibidores-de-los-puntos-de-control-inmunitario-en-diversos-tipos-de-tumores-un-analisis-reconstruido-de-datos-individuales-de-pacientes 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2087/acquired-resistance-to-immune-checkpoint-inhibitors-across-tumor-types-a-reconstructed-individual-patient-data-analysis 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2086/aprendizaje-profundo-basado-en-laminas-histologicas-de-cd3-para-la-prediccion-del-pronostico-del-cancer-de-colon-analisis-de-tres-cohortes-internacionales-de-cancer-de-colon-en-estadio-iii 2026-06-02 monthly 0.5 https://crcwarriors.org/articulo/2086/deep-learning-based-on-cd3-histological-slides-for-prediction-of-colon-cancer-outcome-analysis-of-three-international-stage-iii-colon-cancer-cohorts 2026-06-02 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-05-31 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-05-30 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-05-30 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-05-31 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-06-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-06-01 monthly 0.4